SECURITIES AND EXCHANGE COMMISSION
			  Washington, D.C.  20549

				 FORM 10-KSB
(Mark One)

[X]     ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
	 EXCHANGE ACT OF 1934
	For the fiscal year ended July 31, 2002

	OR

[ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
	 EXCHANGE ACT OF 1934
	For the transition period from ___________ to ____________

			Commission file No. 000-23399

			       NOVADEL PHARMA INC.
	    ---------------------------------------------------------
	   (Name of small business issuer as specified in its charter)

       Delaware                                       22-2407152
 -----------------------------------------------------------------------------
(State or other jurisdiction of          (I.R.S. Employer Identification No.)
 incorporation or organization)

31 State Highway 12 Flemington, New Jersey                08822
 -----------------------------------------------------------------------------
(Address of principal executive offices)               (Zip Code)


Issuer's telephone number, including area code: (908) 782-3431
						---------------

Securities registered pursuant to Section 12(b) of the Exchange Act:  None

Securities registered pursuant to Section 12(g) of the Exchange Act:

     Common Stock, par value $.001 per share
     Redeemable Common Stock Purchase Warrants

     Indicate by check mark whether the issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes  [X]    No [ ]

     Check if there is no disclosure of delinquent filings pursuant to Item
405 of Regulation S-B contained herein, and no disclosure will be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [X].

     State the issuer's revenues for its most recent fiscal year:  $339,000

     The aggregate market value of the voting and non-voting common equity of
the registrant held by non-affiliates of the registrant at October 21, 2002
was approximately $ 9,293,000 based upon the closing sale price of $1.35 for
the Registrant's Common Stock, $.001 par value, as reported by the National
Association of Securities Dealers OTC Bulletin Board on October 21, 2002.

     As of October 21, 2002 the Registrant had 14,526,974 shares of Common
Stock, $.001 par value, outstanding.

     Documents incorporated by reference:    None



<PAGE>

			    NOVADEL PHARMA INC.
	     (Formerly Flemington Pharmaceutical Corporation)

		       Annual Report on Form 10-KSB
		 For the Fiscal Year Ended July 31, 2002

			     TABLE OF CONTENTS

							     Page
							    ------
				  PART  I

Item 1.  Business                                              1
Item 2.  Properties                                           20
Item 3.  Legal Proceedings                                    20
Item 4.  Submission of Matters to a Vote of Security
	  Holders                                             21

				 PART  II


Item 5.  Market for the Registrant's Common Stock and
	  Related Security Holder Matters                     22
Item 6.  Management's Discussion and Analysis of Financial
	  Condition and Results of Operations                 23
Item 7.  Financial Statements                                 25
Item 8.  Changes in and Disagreements with Accountants on
	  Accounting and Financial Disclosure                 26


				PART  III

Item 9.  Directors, Executive Officers, Control Persons,
	  etc.                                                26
Item 10. Executive Compensation                               28
Item 11. Security Ownership of Certain Beneficial Owners
	  and Management                                      33
Item 12. Certain Relationships and Related Transactions       36


				PART  IV

Item 13. Exhibits List and Reports on Form 8-K                37
Item 14. Controls and Procedures                              40



<PAGE>


				PART I

ITEM 1. BUSINESS.

General

	NOVADEL PHARMA INC., a Delaware corporation ( "NovaDel" or the
"Company") (formerly known as Flemington Pharmaceutical Corporation), is
engaged in the development of novel application drug delivery systems for
presently marketed prescription and over-the-counter ("OTC") drugs.  The
Company's (both patented and patent-pending) delivery systems are lingual
sprays, enabling drug absorption through the oral mucosa and more rapid
absorption into the bloodstream than presently available oral delivery
systems.  The Company's proprietary delivery system enhances and greatly
accelerates the onset of the therapeutic benefits which the drugs are
intended to produce.  The Company refers to its delivery system as Immediate-
Immediate Release (I2RTM) because its delivery system is designed to provide
therapeutic benefits within minutes of administration.  The Company's
development efforts for its novel drug delivery system are concentrated on
drugs which are already available and proven in the marketplace.  In addition
to increasing bioavailability by avoiding metabolism by the liver
before entry into the bloodstream, the Company believes that its proprietary
delivery system offers the following significant advantages:  (i) improved
drug safety profile by reducing the required dosage, including possible
reduction of side-effects; (ii) improved dosage reliability; (iii) allowing
medication to be taken without water; and (iv) improved patient convenience
and compliance.

	In light of the material expense and delays associated with
independently developing and obtaining approval of pharmaceutical products,
the Company will seek to develop such products through collaborative
arrangements with major pharmaceutical companies, which will fund that
development.  Due to the Company's small revenue base, low level of working
capital and inability to include the number of development agreements with
pharmaceutical companies, the Company has been unable aggressively to pursue
its product development strategy. The Company will require significant
additional financing and/or a strategic alliance with a well-funded
development partner to undertake its business plan. See "Management
Discussion and Analysis."

	At its inception in 1982, the Company was a consultant to the
pharmaceutical industry, focusing on product development activities of various
European pharmaceutical companies. Since 1992 the Company has used its
consulting revenues to fund its own product development activities.  The
Company's focus on developing its own products evolved naturally out of its
consulting experience for other pharmaceutical companies.  Substantially all
of the Company's revenues previously were derived from its consulting
activities.  In 1998, the Company changed the name under which it performed
its consulting activities from Pharmaconsult to FPC Consulting.  Effective
October 1, 2002, the Company changed its corporate name from Flemington
Pharmaceutical Corporation to Novadel Pharma Inc. The Company's principal
business address is 31 State Highway 12, Flemington, New Jersey, 08822, and
its telephone number is (908) 782-3431.



				 -1-

<PAGE>


Safe harbor statements under the private securities litigation reform act of
1995

	This Annual Report includes "forward-looking statements" as that term
is defined in the Private Securities Litigation Reform Act of 1995. The safe
harbor provisions of the Securities Exchange Act of 1934 and the Securities
Act of 1933 apply to forward-looking statements made by us. These statements
can be identified by the use of forward-looking terminology such as
"believes," "expects," "may," "will," "should," "plans," "future," "intends,"
"continue," "estimate" or "anticipates" or the negatives or variations of
these terms, and other comparable terminology. In addition, any statements
discussing strategy that involve risks and uncertainties are forward-looking.

	Forward-looking statements involve risks and uncertainties, including
those risks and uncertainties identified in, or incorporated by reference
into, this report. Due to these risks and uncertainties, the actual results
that we achieve may differ materially from these forward-looking statements.
These forward-looking statements are based on current expectations, and we
assume no obligation to update this information. In preparing this report,
we may have made a number of assumptions and projections about the future of
our business. These assumptions and projections could be wrong for several
reasons including, but not limited to, those factors identified in the "Risk
Factors" section, below.

	You are urged to carefully review and consider the various disclosures
that we make in this report .These disclosures attempt to advise interested
parties of the risk factors that may affect our business and the market price
of our shares of common stock.


Recent Developments

Private Placement.

	In December 2001 and February 2002, the Company successfully closed
private placements of 4,000,000 shares and 2,666,667 shares, respectively,
of its common stock, par value $.001 per share, at a per share price of $.75.
In addition to the shares, the placement included an equal number of warrants
to purchase additional shares in the same number at a price of $0.75 per share.
The Company received aggregate net proceeds of approximately $4,916,000.
See "Certain Relationships at Related Transactions".

Product Development

	The Company has the following products under active development, with
clinical trials either having been performed or currently under way, pursuant
to open INDs.

Loratadine Lingual Spray

	A loratadine lingual spray formulation has been developed and
successfully undergone stability testing. A Pre-IND meeting with FDA was held
in the third quarter of 2000 and based on the results of that meeting a plan
for further development was prepared.  An IND was filed and a pharmacokinetic
study was carried out under this IND to compare the plasma levels following



				  -2-

<PAGE>


administration of a 5.0 mg and a 2.5 mg lingual spray to those after
administration of a 10 mg tablet. Both lingual spray doses resulted in higher
plasma levels concentrations than the 10 mg tablet.  In the case of the 5.0
mg dose the peak plasma levels were greater than twice those of the tablet
and those after the 2.5 mg dose were about 50% higher.  Therapeutic plasma
levels based on the claimed start of antihistaminic effect for the Claritin(r)
tablet (1-3 hours) were achieved between 24 and thirty minutes.  The company
is presently seeking a partner to develop this product.

Clemastine Lingual Spray

	The formulation of clemastine lingual spray that was terminated by
Novartis in 1998 was revised and a Pre-IND meeting with FDA was held in the
third quarter of 2000.  Based on the results of that meeting a plan for
further development was prepared and an IND was filed.  A pilot nasal
challenge efficacy study was initiated in the second quarter of 2000. This
study tested the relative response of subjects challenged with allergy
producing substances to an OTC tablet (1.34 mg) and a lingual spray dose of
0.68 mg.  The antihistamine was administered 15 minutes prior to the challenge.
The results showed that the spray had the same antihistaminic effect as the
tablet when compared to placebo at 45 minutes after dosing even though the
dose was only half that of the tablet.  Eight of the parameters measured in
the study showed a clear trend that the spray was better than the tablet and
the tablet was better than placebo.  Even though the study was only a pilot
study, the results appear to support the concept that a clemastine lingual
spray could be the first OTC non-sedating antihistamine product in that there
were two cases of drowsiness when the tablet was given and one with the
placebo but none when the lingual spray was administered.  A larger
confirmatory study as well as other pilot studies are planned.  The company
is seeking a partner to develop this product.

Estradiol Sprays

	The Company presently has two open IND's for the study of Estradiol
therapies.  Due to questions that recently have been raised about estrogen
therapy, the Company is reevaluating the viability of this development
program.

Business Strategy

	The Company's strategy is to concentrate its product development
activities primarily on those pharmaceuticals for which there already are
significant prescription and OTC sales, where the use of the Company's
innovative delivery system will greatly enhance speed of onset of therapeutic
effect, reduce side effects through a reduction of the amount of active drug
substance required to produce a given therapeutic effect, and improve patient
convenience or compliance.

	In light of the material expense and delays associated with
independently developing and obtaining approval of pharmaceutical products,
the Company will seek to develop such products through collaborative
arrangements with major pharmaceutical companies, which will fund that
development. The Company's lack of working capital has impaired its ability
to pursue its strategy.  See "Management Discussion and Analysis."

Patented and Patent Pending Delivery Systems

				  -3-

<PAGE>

	NovaDel has certain patents and pending patent applications for its
Lingual (Oral) Spray delivery system. FDA approval is not a prerequisite for
patent approval.  The expected year of marketability of a given product will
vary depending upon the specific drug product with which the delivery system
will be utilized.  Each individual use of the delivery system will require
registration with and/or approval by the FDA prior to marketability, and the
amount of regulatory oversight required by the FDA will also depend on the
specific type of drug product for which the delivery system is implemented.
The following is a description of the oral dosage delivery system for which
patent applications are either granted or pending.

	Lingual (Oral) Spray.  The Company's aerosol and pump spray
formulations release the drug in the form of a fine mist into the mouth for
immediate absorption into the bloodstream via the mucosal membranes.  The
Company believes that this delivery system offers certain advantages,
including improving the safety profile of certain drugs by lowering the
required dosage, improving dose reliability, and allowing medication to be
taken without water.  Drug absorption through the mucosal membranes of the
mouth is rapid and minimizes the first-pass metabolism effect (i.e., total
or partial inactivation of a drug as it passes through the gastrointestinal
tract and liver).

Proposed Products

	The Company's proposed products described below are subjected to
laboratory testing and stability studies and tested for therapeutic comparison
to the originators' products by qualified laboratories and clinics.  To the
extent that two drug products with the same active ingredients are
substantially identical in terms of their rate and extent of absorption in
the human body (bioavailability), they are considered bioequivalent.  If the
accumulated data demonstrates bioequivalency, submission is then made to the
FDA (through the filing of an ANDA) for its review and approval to manufacture
and market.  If the accumulated data demonstrates that there are differences
in the two drugs' rate and extent of absorption into the human body, or if it
is intended to make additional or different claims regarding therapeutic
effect for the newly developed product, submission is made to the FDA via a
NDA for its review and approval under Section 505(1)(b)(2) or Section
505(b)(2) of the FDC Act.  An NDA submitted under these sections of the FDC
Act are generally less complex than an ordinary NDA and are usually acted upon
by FDA in a shorter period of time.  It is the Company's expectation that the
majority of its products in development will require the filing of these
shorter versions of an NDA because the products are known chemical entities,
but the Company or its licensees will be making new claims as to therapeutic
effects or lessened side effects, or both.

	The Company estimates that development of new formulations of
pharmaceutical products, including formulation, testing and obtaining FDA
approval, generally takes three to five years for the ANDA process.
Development of products requiring additional clinical studies under Section
505(b)(2) NDAs, may take four to seven years.  There can be no assurance that
the Company's determinations will prove to be accurate or that pre-marketing
approval relating to its proposed products will be obtained on a timely basis,
or at all.  See "Government Regulation."

	The Company's currently proposed products fall into the following
therapeutic classes:

* Cardiovascular (Nitroglycerin)


				  -4-

<PAGE>


	The Company's Nitroglycerin product has been formulated and stability
testing has been completed. A United States patent was issued in 1999.  An
IND was filed with FDA in early 2002 and clinical trials began in July 2002.
The Company anticipates filing an NDA in the first quarter of 2003.

* Loratadine Lingual Spray

	A loratadine lingual spray formulation has been developed and
successfully undergone stability testing. An IND was filed in the fourth
quarter of 2000 and a pharmacokinetic study was completed in the second
quarter of 2001. A phase II clinical trial is presently in progress.  The
Company anticipates filing an NDA in 2003.

* Clemastine Lingual Spray

	The formulation of clemastine lingual spray was revised, and an IND was
filed.  A pilot nasal challenge efficacy study was initiated in the second
quarter of 2000. and was completed in the fourth quarter of 2000.  This study
tested the relative response of subjects challenged with allergy producing
substances to an OTC tablet (1.34 mg) and a lingual spray dose of 0.68 mg.
The antihistamine was administered 15 minutes prior to the challenge. The
results showed that the spray had the same antihistaminic effect as the tablet
when compared to placebo at 45 minutes after dosing even though the dose was
only half that of the tablet.  Eight of the parameters measured in the study
showed a clear trend that the spray was better than the tablet and the tablet
was better than placebo.  Even though the study was only a pilot study, the
results support the concept that a clemastine lingual spray could be the first
OTC non-sedating antihistamine product in that there were two cases of
drowsiness when the tablet was given and one with the placebo but none when
the lingual spray was administered.  A larger confirmatory study, as well as
other pilot studies, is planned.  The Company is seeking a partner to develop
this product.

Marketing and Distribution

	The Company intends, generally, to license products developed with
its technology to other drug companies, or to market its products to
pharmaceutical wholesalers, drug distributors, drugstore chains, hospitals,
United States governmental agencies, health maintenance organizations and
other drug companies.  It is anticipated that promotion of the Company's
proposed products will be characterized by an emphasis on their distinguishing
characteristics, such as dosage form and packaging, as well as possible
therapeutic advantages of such products.  The Company will seek to position
its proposed products as alternatives or as line extensions to brand-name
products.  The Company believes that to the extent that the Company's
formulated products are patent-protected, such formulations may offer brand-
name manufacturers the opportunity to expand their product lines.
Alternatively, products which are not patented may be offered to brand-name
manufacturers as substitute products after patent protection on existing
products expire.

	Inasmuch as the Company does not have the financial or other resources
to undertake extensive marketing activities, the Company generally intends to
seek to enter into marketing arrangements, including possible joint ventures
or license or distribution arrangements, with third parties.


				  -5-

<PAGE>


	The Company believes that such third-party arrangements will permit
the Company to maximize the promotion and distribution of its products while
minimizing the Company's direct marketing and distribution costs.  Other than
the Company's aforementioned agreements for the Company's proposed lingual
spray products for angina, the Company has not entered into any agreements or
arrangements with respect to the marketing of its proposed products and there
can be no assurance that it will do so in the future.  There can be no
assurance that the Company's proposed products can be successfully marketed.

	Strategies relating to marketing of the Company's other proposed
formulated products have not yet been determined; these will be formulated in
advance of anticipated completion of development activities relating to the
particular formulated product. The Company has no experience in marketing or
distribution of its proposed proprietary products, and the Company's ability
to fund such marketing activities will require the Company to raise additional
funds and/or consummate a strategic alliance or combination with a well-funded
business partner.

Manufacturing

	The Company has determined to internalize the manufacturing of its
proposed products. Presently, it has established a pilot manufacturing
facility at its present location, which it believes is adequate for its needs
in manufacturing its requirements for formulation development, stability
testing and clinical supplies. It is also presently in negotiations for a new,
larger facility which will have adequate space for its future foreseeable
requirements for production manufacturing and warehouse space. There can be
no assurance, however, that the Company will be successful in concluding such
negotiations, or that it will be successful in constructing and maintaining
such a manufacturing and warehousing facility in compliance with cGMP. If it
is unable to do so, it will become necessary for the Company to make
arrangements with a third party contract manufacturer to satisfy the Company's
requirements. There can be no assurance that, if necessary, the Company will
be able to do so, or be able to do so on commercially satisfactory terms.
Failure of the Company to complete successfully the internalization of its
manufacturing requirements, or to conclude an alternative contract
manufacturing arrangement, could have an adverse effect on the Company's
efforts to obtain regulatory approval for or to commercialize its products.

	It is anticipated that the Company will arrange with third-party
suppliers for supplies of active and inactive pharmaceutical ingredients and
packaging materials used in the manufacture of the Company's proposed products.
It is the Company's present intent to seek to enter into similar manufacturing
arrangements for other products to be developed by it in the future.

	The manufacture of the Company's pharmaceutical products will be
subject to current Good Manufacturing Processes ("cGMP") prescribed by the
FDA, and pre-approval inspections by the FDA and foreign authorities prior
to the commercial manufacture of any such products.  See "Government
Regulation" and "Raw Materials and Suppliers."

	In addition, the raw materials necessary for the manufacture of the
Company's products will, in all likelihood, be purchased by the Company from
suppliers in the United States, Europe and Japan and delivered to its
manufacturing facility by such suppliers.

				  -6-

<PAGE>


	Accordingly, the Company may be subject to various import duties
applicable to both finished products and raw materials and may be affected by
various other import and export restrictions as well as other developments
impacting upon international trade.  These international trade factors will,
under certain circumstances, have an impact on the manufacturing cost (which
will, in turn, have an impact on the cost to the Company of the manufactured
product).  To the extent that transactions relating to the purchase of raw
materials involve currencies other than United States dollars (e.g., Swiss
francs and German marks), the operating results of the Company will be
affected by fluctuations in foreign currency exchange rates.

Raw Materials and Suppliers

	The Company believes that the active ingredients used in the
manufacture of its proposed pharmaceutical products are presently available
from numerous suppliers located in the United States, Europe and Japan.
Generally, certain raw materials, including inactive ingredients, are
available from a limited number of suppliers and certain packaging materials
intended for use in connection with the Company's lingual spray products may
be only available from sole source suppliers.  Although the Company believes
that it will not encounter difficulties in obtaining the inactive ingredients
or packaging materials necessary for the manufacture of its products, there
can be no assurance that the Company will be able to enter into satisfactory
agreements or arrangements for the purchase of commercial quantities of such
materials.  The failure to enter into agreements or otherwise arrange for
adequate or timely supplies of principal raw materials and the possible
inability to secure alternative sources of raw material supplies could have a
material adverse effect on the ability to manufacture formulated products.

	Development and regulatory approval of the Company's pharmaceutical
products are dependent upon the Company's ability to procure active ingredients
and certain packaging materials from FDA-approved sources.  Since the FDA
approval process requires manufacturers to specify their proposed suppliers
of active ingredients and certain packaging materials in their applications,
FDA approval of a supplemental application to use a new supplier would be
required if active ingredients or such packaging materials were no longer
available from the specified supplier, which could result in manufacturing
delays.  Accordingly, the Company will seek to locate alternative FDA approved
suppliers.

Government Regulation

	The development, manufacture and commercialization of pharmaceutical
products are generally subject to extensive regulation by various federal and
state governmental entities.  The FDA, which is the principal United States
regulatory authority, has the power to seize adulterated or misbranded
products and unapproved new drugs, to request their recall from the market,
to enjoin further manufacture or sale, to publicize certain facts concerning
a product and to initiate criminal proceedings.  As a result of federal
statutes and FDA regulations, pursuant to which new pharmaceuticals are
required to undergo extensive and rigorous testing, obtaining pre-market
regulatory approval requires extensive time and expenditures.

	Under the Food, Drug and Cosmetic (FDC) Act, a new drug may not be
commercialized or otherwise distributed in the United States without the prior
approval of the FDA.

				  -7-

<PAGE>


	The FDA approval process relating to a new drug differs, depending on
the nature of the particular drug for which approval is sought.  With respect
to any drug product with active ingredients not previously approved by the
FDA, a prospective drug manufacturer is required to submit a NDA, including
complete reports of pre-clinical, clinical and laboratory studies to prove
such product's safety and efficacy.  The NDA process generally requires,
before the submission of the NDA, submission of an IND pursuant to which
permission is sought to begin preliminary clinical testing of the new drug.
An NDA based on published safety and efficacy studies conducted by others may
also be required to be submitted for a drug product with a previously approved
active ingredient, if the method of delivery, strength or dosage is changed.
Alternatively, a drug having the same active ingredients as a drug previously
approved by the FDA may be eligible to be submitted under an ANDA, which is
significantly less stringent than the NDA approval process.

	While the ANDA process requires a manufacturer to establish
bioequivalence to the previously approved drug, it permits the manufacturer
to rely on the safety and efficacy studies contained in the NDA for the
previously approved drug.

	The NDA approval process generally requires between four to seven
years from NDA submission to pre-marketing approval, although in the case of
an NDA submitted pursuant to Section 505(b)(2) of the Act this time frame may
be significantly shorter.  The Company believes that products developed in
lingual spray delivery systems (dosage forms) usually will require submission
of an NDA under Section 505(b)(2).

	The Company estimates that the development of new formulations of
pharmaceutical products, including formulation, testing and obtaining FDA
approval, generally takes four to seven years for the NDA process, although
NDAs submitted under Section 505(b)(2) are generally less complex than an
ordinary NDA and are usually acted upon by the FDA in a shorter period of
time.  There can be no assurance that the Company's determinations will prove
to be accurate or that pre-marketing approval relating to its proposed products
will be obtained on a timely basis, or at all.  The FDA application procedure
has become more rigorous and costly and the FDA currently performs pre-approval
and periodic inspections of each finished dosage form and each active
ingredient.

	The manufacture of the Company's pharmaceutical products will be
subject to cGMP prescribed by the FDA, pre-approval inspection by the FDA
before beginning commercial manufacture of such products and periodic cGMP
compliance inspections by the FDA thereafter.


Competition

	The markets which the Company intends to enter are characterized by
intense competition.  The Company will be competing against established
pharmaceutical companies which currently market products which are equivalent
or functionally similar to those the Company intends to market.  Prices of
drug products are significantly affected by competitive factors and tend to
decline as competition increases.  In addition, numerous companies are
developing or may, in the future, engage in the development of products
competitive with the Company's proposed products.  The Company expects that
technological developments will occur at a rapid rate and that competition


				  -8-


<PAGE>


is likely to intensify as enhanced delivery system technologies gain greater
acceptance.  Additionally, the markets for formulated products which the
Company has targeted for development are intensely competitive, involving
numerous competitors and products.  The Company will seek to enhance its
competitive position by focusing its efforts on its novel dosage forms.


Patents and Protection of Proprietary Information

	The Company has applied for United States and foreign patent
protection for the delivery system which is the primary focus of its
development activities as well as the delayed contact allergy topical
formulations.  Four United States patents have been issued and other
applications are pending.  There can be no assurance, however, that any
additional patent applications will be granted, or, if granted, will provide
any adequate protection to the Company. The Company also intends to rely on
whatever protection the law affords to trade secrets, including unpatented
know-how.  Other companies, however, may independently develop equivalent or
superior technologies or processes and may obtain patent or similar rights
with respect thereto.

	Although the Company believes that its technology has been developed
independently and does not infringe on the patents of others, there can be no
assurance that the technology does not and will not infringe on the patents
of others.  In the event of infringement, the Company could, under certain
circumstances, be required to modify the infringing process or obtain a
license. There can be no assurance that the Company would be able to do either
of those things in a timely manner or at all, and failure to do so could have
a material adverse effect on the Company and its business.  In addition, there
can be no assurance that the Company will have the financial or other
resources necessary to enforce or defend a patent infringement or proprietary
rights violation action.  If any of the products developed by the Company
infringe upon the patent or proprietary rights of others, the Company could,
under certain circumstances, be enjoined or become liable for damages, which
would have a material adverse effect on the Company.

	The Company also relies on confidentiality and nondisclosure
arrangements with its licensees and potential development candidates.  There
can be no assurance that other companies will not acquire information which
the Company considers to be proprietary.  Moreover, there can be no assurance
that other companies will not independently develop know-how comparable to or
superior to that of the Company.

	Buccal Nonpolar Spray.  On April 12, 1996 the Company filed an
application with the United States Patent and Trademark Office ("PTO") for
protection of this subject matter.  On September 1, 1998 the PTO allowed the
claims directed to sprays, but rejected the claims directed to the capsules.
In October 1998 the Company dropped the capsule claims from this application,
to pursue allowance and issuance of a patent directed to the spray claims.
On October 21, 1999 the PTO issued a patent to the Company on the spray claims
(#5955098).

	On February 21, 1997, the Company filed an application under the
Patent Cooperation Treaty ("PCT") for the above-subject matter.  The
International Preliminary Examination Authority has issued an opinion in
which the PCT examiner determined that the subject matter of the invention
while novel, is not inventive for obviousness.


				  -9-

<PAGE>

	This opinion, with which the Company disagrees, is not dispositive,
however, it may be highly persuasive in subsequent proceedings in the European
and individual national patent offices should the Company decide to proceed
in these jurisdictions.

	In October 1998, the Company filed a patent application in the
European Patent Office and in Canada for the buccal nonpolar spray claims.
The former has not yet been acted upon; the latter is not yet due for
examination.

	 Buccal Polar Spray.  On April 12, 1996, the Company filed an
application in the PTO directed to the buccal polar spray.  The PTO allowed
the claims directed to sprays, but rejected the claims directed to the
capsules.  The Company dropped the capsule claims from this application, to
pursue allowance and issuance of a patent directed to the spray claims and
subsequently the PTO issued a patent to the Company on the spray claims.  In
October 1998, the Company filed a patent application in Canada for the buccal
nonpolar spray claims.

	 On February 21, 1997 the Company filed a PCT application directed to
the foregoing subject matter.  The situation with respect to this subject
matter is the same as that of the counterpart PCT application directed to
buccal nonpolar spray or capsule discussed above. The Company has dropped the
two bite capsule parts and individually filed for patent protection in Canada
and Europe for the three spray inventions.

	In October and November 1998, the Company filed patent applications
in Europe and Canada for the buccal polar spray claims.  In the former case an
Official action has been received and responded to.  The latter is not ripe
for examination yet.

	Buccal Nonpolar Spray for Nitroglycerin.  On April 12, 1996, the
Company filed an application in the PTO directed to the above subject matter;
no claims were allowed. On November 25, 1998, the Company filed the
application in the PTO, directed to the method of use of the spray.
Subsequently, the PTO issued a patent (#5869002) on those claims. On February
21, 1997, the Company filed a PCT application directed to the above subject
matter.  The application was rejected  for lack of inventive step on the
ground that the manner in which the claims differed from the prior art was
required by legislation. European and Canadian counterpart applications have
been filed. The Canadian application is not yet ripe for examination.

	Buccal/Polar/Nonpolar Sprays or Capsule (Different Medicaments as
Above).  An application was filed with the PCT on October 1, 1997 designating
a large number of possible countries including the United States.  This
application differs from the first two applications above in that it utilizes
different ingredients.  The PCT Examiner allowed two rather limited (but not
commercially insignificant) claims and rejected the remaining claims for lack
of inventiveness and lack of unity.  The Company has made individual filings
for patent protection in USA, Japan, Canada, and Europe.

	In the United States, the original application has been refiled as a
CIP (008) directed only to pump spray compositions.  An initial Official
Action has been received and responded to.  No examination is yet due in
Japan and Canada.  Upon advice of our European Associate, the original
application was filed as three separate divisional applications.   While some


				  -10-

<PAGE>

new references have been cited no Official Action has been received in any of
these cases.

	Antihistamine Syrup and Ointment.  On November 10, 1997 the Company
filed an application with the U.S. PTO for protection of its antihistamine
syrup and ointments, a technology to be used in the Company's proposed poison
ivy product.  In October 1998, the PTO initially rejected the application,
which was then refilled in May 2000 with claims directed solely to method of
protection. On May 21, 2002 the PTO granted the Company's patent application.

	General Comment with Respect to the Foregoing PCT Applications.  The
Company is interested in obtaining patent protection in Europe and Canada.
It is to be expected that the same examiner who examined these applications
as a PCT examiner will be the examiner who will handle these applications in
the European "National" Phase.  Hence, the Company anticipates that in the
case of the European applications, it may be necessary to appeal to the Board
of Appeals in Munich.  At the present time, it is not possible accurately to
predict the expenses involved in pursuing the foregoing applications.  However,
expenses may exceed $100,000 (in the aggregate for all three applications)
before a final disposition is obtained.  The Company expects this process to
take between two and four years.

Product Liability

	The Company may be exposed to potential product liability claims by
consumers. The Company does not presently maintain product liability insurance
coverage.  Although the Company will seek to obtain product liability
insurance prior to the commercialization of any products, there can be no
assurance that the Company will obtain such insurance or, if obtained, that
any such insurance will be sufficient to cover all possible liabilities.  In
the event of a successful suit against the Company, insufficiency of insurance
coverage could have a material adverse effect on the Company.  In addition,
certain food and drug retailers require minimum product liability insurance
coverage as a condition precedent to purchasing or accepting products for
retail distribution.  Failure to satisfy such insurance requirements could
impede the ability of the Company or its distributors to achieve broad retail
distribution of its proposed products, which would have a material adverse
effect upon the business and financial condition of the Company.

Customer Dependence

	Since inception, substantially all of the Company's revenues have been
derived from consulting activities primarily in connection with product
development for various pharmaceutical companies.  Among other things, the
Company worked with its European clients to obtain regulatory approvals for
new drug formulations in the United States.  As the Company has increasingly
concentrated its attention and activities on developing its own products, its
consulting activities have diminished. For the year ended July 31, 2002,
consulting activities relating to the Company's two (2) largest clients
accounted for approximately 46.2% and 39.3% respectively, of the Company's
revenue. For the year ended July 31, 2001, consulting activities relating to
the Company's two largest clients accounted for approximately 40% and 18%
respectively, of the Company's revenue.

				  -11-

<PAGE>


Employees

	The Company currently has fifteen (15) full-time employees, four (4)
of whom are executive officers of the Company, seven (7) of whom are
laboratory or support personnel and four (4) of whom are engaged in
administrative functions. The success of the Company will be dependent in
part, upon its ability to hire and retain additional qualified sales,
manufacturing and distribution personnel, however, there can be no assurance
that the Company will be able to hire or retain such necessary personnel.


			      Risk factors

	You should carefully consider the following risk factors and all other
information contained in this Annual Report before investing in our common
stock.  Investing in our common stock involves a high degree of risk.  Any of
the following risks could adversely affect our business, financial condition
and results of operations and could result in a complete loss of your
investment.  The risks and uncertainties described below are not the only
ones we may face.

	We have a history of losses

	We had an accumulated deficit at July 31, 2002 of approximately
$9,813,000.  We incurred operating losses in all of the last fiscal years
ended July 31 including a net loss of approximately $4,290,000 for the year
ended July 31, 2002.   Because we increased our product development activities,
we anticipate that we will incur substantial operating expenses in connection
with continued development, testing and approval of our proposed products, and
expect these expenses will result in continuing and, perhaps, significant
operating losses until such time, if ever, that we are able to achieve
adequate product sales levels. Because our rate of expenses is high and our
very limited resources, the Company's auditors have qualified their audit
opinion with regard to the Company's ability to continue as a going concern.

	We will require significant capital requirements for product
development and commercialization

	We have significant capital requirements necessary to fund planned
expenditures in connection with the research, development, testing and approval
of our proposed products.  We anticipate, based on our current proposed plans
and assumptions relating to our operations (including the timetable of, and
costs associated with, new product development), that the proceeds of our 2001
and 2002 private placements and projected cash flow from operations will be
sufficient to satisfy our contemplated cash requirements for at least 5 months
from the date of this report.  Due to our small revenue base, low level of
working capital and inability to increase the number of development agreements
with pharmaceutical companies, we have been unable to aggressively pursue our
product development strategy.  We will require significant additional
financing and/or a strategic alliance with a well-funded development partner
to aggressively pursue our business plan.  We have no current arrangements
with respect to, or sources of, additional financing, and there can be no
assurance that additional financing will be available to us on acceptable
terms, if at all.  Unless we raise additional financing or significantly
reduce our expenses, we will not have sufficient funds and we will not be to
complete development and commercialization of our proposed products or
continue operating.

				  -12-

<PAGE>

	See "Management's Discussion and Analysis of Financial Condition and
Results of Operations."

	We are dependent on principal clients

	To date, substantially all of our revenues have been derived from
consulting services rendered to a limited number of clients, the loss of
certain of which would have an adverse effect on us.  For the year ended July
31, 2002, consulting activities relating to our two (2) largest clients, with
which we have written agreements, accounted for approximately 46%, and 40%
respectively, of our revenues.  There can be no assurance that our clients
will continue to seek consulting services from us or that we will continue to
provide consulting services to the industry. See "Business- Customer
Dependence."

	Our business is evolving

	Although we have received revenue from our own product development
activities, these revenues are insignificant as compared to our revenues from
product development consultation work done for our clients.  The nature of our
revenue received from our own product development consists of payments by
pharmaceutical companies for research and bioavailability studies, pilot
clinical trials, and similar milestone-related payments.  Subject to additional
funding, we expect to continue our consulting activities despite increasing
our product development activities.  Our future growth and profitability will
be dependent upon our ability to successfully raise additional funds to
complete the development of, obtain regulatory approvals for, and license out
or market, our own proposed products.  Accordingly, our prospects must be
considered in light of the risks, expenses and difficulties frequently
encountered in connection with the establishment of a new business in a highly
competitive industry, characterized by frequent new product introductions.
We anticipate that we will incur substantial operating expenses in connection
with the development, testing and approval of our proposed products and expect
these expenses to result in continuing and, perhaps, significant operating
losses until such time, if ever, that we are able to achieve adequate levels
of sales or license revenues. There can be no assurance that we will be able
to raise additional financing, increase revenues significantly, or achieve
profitable operations.

	We do not have commercially available products

	Our principal efforts are the development of, and obtaining regulatory
approvals for, our proposed products.  We anticipate that marketing activities
for our proprietary products, whether by us or one or more licensees, will not
begin until 2003 at the earliest.  Accordingly, it is not anticipated that we
will generate any revenues from royalties or sales of proprietary products
until regulatory approvals are obtained and marketing activities begin.  There
can be no assurance that any of the proposed proprietary products will prove
to be commercially viable, or if viable, that they will reach the marketplace
on the timetables desired by us.  The failure or the delay of these products
to achieve commercial viability would have a material adverse effect on us.
See  "Business - Proposed Products" and " - Government Regulation."


				  -13-

<PAGE>

	We have not completed product development

	The development of our proposed products has not been completed and we
will be required to devote considerable effort and expenditures to complete
such development.  In addition to obtaining adequate financing, satisfactory
completion of development, testing, government approval and sufficient
production levels of such products must be obtained before the proposed
products will become available for commercial sale.  We do not anticipate
generating material revenue from product sales until perhaps 2003 or
thereafter.  Other potential products remain in the conceptual or very early
development stage and remain subject to all the risks inherent in the
development of pharmaceutical products, including unanticipated development
problems, and possible lack of funds to undertake or continue development.
These factors could result in abandonment or substantial change in the
development of a specific formulated product.  There can be no assurance that
any of our proposed products will be successfully developed, be developed on
a timely basis or be commercially accepted once developed.  The inability to
successfully complete development, or a determination by us, for financial or
other reasons, not to undertake to complete development of any product,
particularly in instances in which we have made significant capital
expenditures, could have a material adverse effect on us.

	We do not have direct consumer marketing experience

	We have no experience in marketing or distribution at the consumer
level of our proposed proprietary products.  Moreover, we do not have the
financial or other resources to undertake extensive marketing and advertising
activities.  Accordingly, we intend generally to rely on marketing
arrangements, including possible joint ventures or license or distribution
arrangements with third parties.  We have not entered into any significant
agreements or arrangements with respect to the marketing of our proposed
products, and there can be no assurance that we will do so in the future or
that any such products can be successfully marketed.  Our strategy to rely on
third party marketing arrangements could adversely affect our profit margins.
See "Business - Marketing and Distribution."

	We must comply with good manufacturing practices

	The manufacture of our pharmaceutical products will be subject to
current Good Manufacturing Practices ("cGMP") prescribed by the FDA, pre-
approval inspections by the FDA or foreign authorities, or both, before
commercial manufacture of any such products and periodic cGMP compliance
inspections thereafter by the FDA.  There can be no assurance that we or any
third party manufacturer will be able to comply with cGMP or satisfy pre- or
post-approval inspections in connection with the manufacture of our proposed
products. Failure or delay by us or any such manufacturer to comply with cGMP
or satisfy pre- or post-approval inspections would have a material adverse
effect on us.  See "Business-- Manufacturing."

	We are dependent on our suppliers

	We believe that the active ingredients used in the manufacture of our
proposed pharmaceutical products are presently available from numerous
suppliers located in the United States, Europe, India and Japan.

				  -14-

<PAGE>
	We believe that certain raw materials, including inactive ingredients,
are available from a limited number of suppliers and that certain packaging
materials intended for use in connection with our spray products currently
are available only from sole source suppliers.  Although we do not believe we
will encounter difficulties in obtaining the inactive ingredients or packaging
materials necessary for the manufacture of our products, there can be no
assurance that we will be able to enter into satisfactory agreements or
arrangements for the purchase of commercial quantities of such materials.
We have a written supply agreement with Dynamit Nobel for certain raw
materials for the nitroglycerin lingual spray product.  With respect to other
suppliers, we operate primarily on a purchase order basis beyond which there
is no contract memorializing our purchasing arrangements.  The inability to
enter into agreements or otherwise arrange for adequate or timely supplies of
principal raw materials and the possible inability to secure alternative
sources of raw material supplies could have a material adverse effect on our
ability to arrange for the manufacture of formulated products. In addition,
development and regulatory approval of our products are dependent upon our
ability to procure active ingredients and certain packaging materials from
FDA-approved sources. Since the FDA approval process requires manufacturers
to specify their proposed suppliers of active ingredients and certain
packaging materials in their applications, FDA approval of a supplemental
application to use a new supplier would be required if active ingredients or
such packaging materials were no longer available from the originally
specified supplier, which could result in manufacturing delays. See "-
Business- Raw Materials and Suppliers."

	We face intense competition

	The markets which we intend to enter are characterized by intense
competition.  We or our licensees may be competing against established
pharmaceutical companies which currently market products which are equivalent
or functionally similar to those we intend to market.  Prices of drug products
are significantly affected by competitive factors and tend to decline as
competition increases.  In addition, numerous companies are developing or may,
in the future, engage in the development of products competitive with our
proposed products.  We expect that technological developments will occur at a
rapid rate and that competition is likely to intensify as enhanced dosage from
technologies gain greater acceptance. Additionally, the markets for formulated
products which we have targeted for development are intensely competitive,
involving numerous competitors and products.  Most of our prospective
competitors possess substantially greater financial, technical and other
resources than us.  Moreover, many of these companies possess greater
marketing capabilities than us, including the resources necessary to enable
them to implement extensive advertising campaigns.  There can be no assurance
that we will have the ability to compete successfully.  See "Business -
Competition."

	The absence of product liability insurance coverage may affect our
business

	We may be exposed to potential product liability claims by consumers.
We presently maintain no product liability insurance coverage.  Although we
will seek to obtain product liability insurance before the commercialization
of any proprietary products, there can be no assurance that we will be able
to obtain such insurance or, if obtained, that any such insurance will be
sufficient to cover all possible liabilities to which we may be exposed.  In
the event of a successful suit against us, insufficiency of insurance coverage
could have a material adverse effect on us.  In addition, certain food and
drug retailers require minimum product liability insurance coverage as

				  -15-

<PAGE>


a condition precedent to purchasing or accepting products for retail
distribution.  Failure to satisfy such insurance requirements could impede
the ability of us or our distributors to achieve broad retail distribution of
our proposed products, which could have a material adverse effect on us.
See "Business - Product Liability."

	Extensive government regulation may affect our business

	The development, manufacture and commercialization of pharmaceutical
products are generally subject to extensive regulation by various federal and
state governmental entities.  The FDA, which is the principal United States
regulatory authority, has the power to seize adulterated or misbranded products
and unapproved new drugs, to request their recall from the market, to enjoin
further manufacture or sale, to publicize certain facts concerning a product
and to initiate criminal proceedings.  As a result of federal statutes and
FDA regulations, pursuant to which new pharmaceuticals are required to
undergo extensive and rigorous testing, obtaining pre-market regulatory
approval requires extensive time and expenditures.  Under the "FDC Act", a
new drug may not be commercialized or otherwise distributed in the United
States without the prior approval of the FDA.  The FDA approval processes
relating to new drugs differ, depending on the nature of the particular drug
for which approval is sought.  With respect to any drug product with active
ingredients not previously approved by the FDA, a prospective drug
manufacturer is required to submit a new drug application ("NDA"), including
complete reports of pre-clinical, clinical and laboratory studies to prove
such product's safety and efficacy. The NDA process generally requires, before
the submission of the NDA, submission of an IND pursuant to which permission
is sought to begin preliminary clinical testing of the new drug.  An NDA,
based on published safety and efficacy studies conducted by others, may also
be required to be submitted for a drug product with a previously approved
active ingredient if the method of delivery, strength or dosage form is
changed. Alternatively, a drug having the same active ingredient as a drug
previously approved by the FDA may be eligible to be submitted under an ANDA,
which is significantly less stringent than the NDA approval process.  While
the ANDA process requires a manufacturer to establish bioequivalence to the
previously approved drug, it permits the manufacturer to rely on the
safety and efficacy studies contained in the DNA for the previously approved
drug. We believe that some of our drug products developed in capsule form
will be substantially similar to products which have previously obtained FDA
approval and, accordingly, that approvals for such products can be obtained
by submitting an ANDA.  We, however, may be required, before submitting an
ANDA, to submit a suitability petition, the purpose of which is to permit the
FDA to evaluate whether a change in strength, dosage form or method of
delivery is significant enough to require clinical trials and, therefore, an
NDA filing.  There can be no assurance that the FDA will not require us to
conduct clinical trials for such products and otherwise comply with the NDA
approval process.  We believe that products developed in spray dosage form
will require submission of an NDA.  We estimate that the development of new
formulations of pharmaceutical products, including formulation, testing and
obtaining FDA approval, generally takes three to five years for the ANDA
process and four to seven years for the NDA process. There can be no assurance
that our determinations will prove to be accurate or that pre-marketing
approval relating to our proposed products will be obtained on a timely basis,
or at all. The failure by us to obtain necessary regulatory approvals, whether
on a timely basis, or at all, would have a material adverse effect on our
business.

				  -16-

<PAGE>

	We are dependent on existing management

	Our success is substantially dependent on the efforts and abilities of
our founder, President and Chief Executive Officer, Harry A. Dugger, III,
Ph.D., our Chairman, John Klein, and our Chief Financial Officer, Donald
Deitman.  Mr. Klein is not required to devote full time to us.  Decisions
concerning our business and our management are and will continue to be made
or significantly influenced by these individuals.  The loss or interruption
of their continued services would have a materially adverse effect on our
business operations and prospects.

	We are controlled by current stockholders, officers and directors

	Management and our affiliates currently beneficially own (including
shares they have the right to acquire) approximately 83% of our common stock.
These persons are and will continue to be able to exercise control over the
election of our directors and the appointment of officers, increase the
authorized capital, dissolve, merge or engage us in other fundamental
corporate transactions.

	There is a potential adverse effect if we redeem our publicly traded
warrants

	The 680,000 warrants issued in connection with our initial public
offering may be redeemed by us, at a redemption price of $.10 per warrant,
upon not less then thirty days prior written notice provided the last sale
price of our common stock on the NASD OTC Bulletin Board, Nasdaq (or another
national securities exchange) for twenty consecutive trading days ending
within three days of the notice of redemption, equals or exceeds 200% of the
current warrant exercise price ($5.80), subject to adjustment.  Redemption
of the warrants could force the holders thereof to exercise the warrants and
pay the exercise price at a time when it may be disadvantageous for the
holders to do so, to sell the warrants at the then current market price when
they might otherwise wish to hold the warrants, or to accept the redemption
price, which is likely to be substantially less than the market value of the
warrants at the time of redemption.  The warrants were due to expire on
November 18, 2002.  In November 2002, the Company decided to extend their
expiration date for a period of one year (i.e. to November 18, 2003).  All
other provisions of the warrants remain unchanged.

	The limited prior public market and trading market may cause possible
volatility in our stock price

	There has only been a limited public market for our securities and
there can be no assurance that an active trading market in our securities will
be maintained.  The OTC Bulletin Board is an unorganized, inter-dealer, over-
the-counter market which provides significantly less liquidity than the Nasdaq
Stock market, and quotes for stocks included on the OTC Bulletin Board are
not listed in the financial sections of newspapers as are those for the Nasdaq
Stock Market.  In addition, the stock market in recent years has experienced
extreme price and volume fluctuations that have particularly affected the
market prices of many smaller companies.  The trading price of our common
stock is expected to be subject to significant fluctuations in response to
variations in quarterly operating results, changes in analysts' earnings
estimates, announcements of innovations by us or our competitors, general
conditions in the industry in which we operate and other factors.  These
fluctuation, as well as general economic and market conditions, may have a
material or adverse effect on the market price of our common stock.


				  -17-

<PAGE>


	Penny stock regulations may impose certain restrictions on
marketability of our securities

	The Securities and Exchange Commission (the "Commission") has adopted
regulations which generally define a "penny stock" to be any equity security
that has a market price (as defined) of less than $5.00 per share or an
exercise price of less than $5.00 per share, subject to certain exceptions.
As a result, our common stock is subject to rules that impose additional sales
practice requirements on broker-dealers who sell such securities to persons
other than established customers and accredited investors (generally those
with assets in excess of $1,000,000 or annual income exceeding $200,000, or
$300,000 together with their spouse).  For transactions covered by these rules,
the broker-dealer must make a special suitability determination for the
purchase of such securities and have received the purchaser's written consent
to the transaction prior to the purchase.  Additionally, for any transaction
involving a penny stock, unless exempt, the rules require the delivery, prior
to the transaction, of a risk disclosure document mandated by the Commission
relating to the penny stock market.  The broker-dealer must also disclose the
commission payable to both the broker-dealer and the registered representative,
current quotations for the securities and, if the broker-dealer is the sole
market maker, the broker-dealer must disclose this fact and the broker-
dealer's presumed control over the market.  Finally, monthly statements must
be sent disclosing recent price information for the penny stock held in the
account and information on the limited market in penny stocks.  Consequently,
the "penny stock" rules may restrict the ability of broker-dealers to sell
our securities and may affect the ability of investors to sell our securities
in the secondary market and the price at which such purchasers can sell any
such securities.

	Shareholders should be aware that, according to the Securities and
Exchange Commission, the market for penny stocks has suffered in recent years
from patterns of fraud and abuse.  Such patterns include:

* control of the market for the security by one or a few broker-dealers that
  are often related to the promoter or issuer;

* manipulation of prices through prearranged matching of purchases and sales
  and false and misleading press releases;

* "boiler room" practices involving high pressure sales tactics and
  unrealistic price projections by inexperienced sales persons;

* excessive and undisclosed bid-ask differentials and markups by selling
  broker-dealers; and

* the wholesale dumping of the same securities by promoters and broker-
  dealers after prices have been manipulated to a desired level, along with
  the inevitable collapse of those prices with consequent investor losses.

	Our management is aware of the abuses that have occurred historically
in the penny stock market.  Although we do not expect to be in a position to
dictate the behavior of the market or of broker-dealers who participate in


				  -18-

<PAGE>


the market, management will strive within the confines of practical
limitations to prevent the described patterns from being established with
respect to our common stock.

     Additional authorized shares of common stock and preferred stock
available for issuance may adversely affect the market

     We are authorized to issue 50,000,000 shares of our common stock.  As of
July 31, 2002 there were 14,448,817 shares of our common stock issued and
outstanding.  However, the total number of shares of common stock issued and
outstanding does not include the exercise of options or warrants.  We have
reserved up to 13,110,281 shares of our common stock for issuance upon
exercise of stock options and warrants.  Of the reserved shares, a total of
2,075,000 shares have been reserved among NovaDel's 1992, 1997 and 1998 Stock
Option Plans, of which options to purchase an aggregate of 500,000, 500,000
and 787,500 shares have been issued under the respective Plans. Another
2,800,000 shares are reserved for issuance and available for the options
granted pursuant to the terms of the employment agreements of Mr. Moroney,
a former director, Dr. Dugger, our CEO, Robert Galler, a director, and John
Klein, our chairman and Mohammed El-Shafy, Vice President of Formulation
Development.  All of such options and warrants contain provisions for cashless
exercise.

	Exercise of the outstanding convertible securities, will reduce the
percentage of common stock held by the public stockholders.  Further, the
terms on which we could obtain additional capital during the life of the
convertible securities may be adversely affected, and it should be expected
that the holders of the convertible securities would exercise them at a time
when we would be able to obtain equity capital on terms more favorable than
those provided for by such convertible securities.  As a result, any issuance
of additional shares of common stock may cause our current shareholders to
suffer significant dilution which may adversely affect the market.

	In addition to the above-referenced shares of common stock which may
be issued without shareholder approval, we have 1,000,000 shares of authorized
preferred stock, the terms of which may be fixed by our Board of Directors.
We presently have no issued and outstanding shares of preferred stock and
while we have no present plans to issue any shares of preferred stock, our
Board of Directors has the authority, without shareholder approval, to create
and issue one or more series of such preferred stock and to determine the
voting, dividend and other rights of holders of such preferred stock.  The
issuance of any of such series of preferred stock could have an adverse effect
on the holders of common stock.

	Shares eligible for future sale may adversely affect the market

	Of the 14,448,817 shares of common stock (as of July 31, 2002) held
by our present stockholders, 7,774,385 shares may be available for public
sale by means of ordinary brokerage transactions in the open market pursuant
to Rule 144, promulgated under the Act, subject to certain limitations.  In
general, under Rule 144, a person (or persons whose shares are aggregated)
who has satisfied a one-year holding period may, under certain circumstances,
sell within any three-month period a number of securities which does not
exceed the greater of 1% of the then outstanding shares of common stock or
the average weekly trading volume of the class during the four calendar weeks
prior to such sale.

				  -19-

<PAGE>


	Rule 144 also permits, under certain circumstances, the sale of
securities, without any limitation, by a person who is not an affiliate of
the Company and who has satisfied a two-year holding period.

	We have reserved up to 13,110,281 shares of common stock for issuance
upon exercise of various stock options and warrants, of which 1,600,000 shares
were registered under a Registration Statement on Form S-8 under the Act (with
the balance registered under a registration statement of which this prospectus
forms a part).  Although all of our officers and directors have executed lock-
up agreements in which they agreed not to publicly offer, sell or otherwise
dispose of directly or indirectly, any of our securities owned by them, until
December 2002 (except that 75% of each such person's shares have already been
released and that on December 12, 2002, all of each such person's remaining
shares become released from such lock-up), any substantial sale of common
stock pursuant to Rule 144 may have an adverse effect on the market price of
our securities.

	Limitation on director/officer liability

	As permitted by Delaware law, our certificate of incorporation limits
the liability of our directors for monetary damages for breach of a director's
fiduciary duty except for liability in certain instances.  As a result of our
charter provision and Delaware law, stockholders may have limited rights to
recover against directors for breach of fiduciary duty.  In addition, our
certificate of incorporation provides that we shall indemnify our directors
and officers to the fullest extent permitted by law.

	We have no history of paying dividends on our common stock

	We have never paid any cash dividends on our common stock and do not
anticipate paying any cash dividends on our common stock in the foreseeable
future.  We plan to retain any future earnings to finance growth.  If we
determine that we will pay dividends to the holders of our common stock, there
is no assurance or guarantee that such dividends will be paid on a timely
basis.


ITEM 2. PROPERTIES

	The Company's executive offices are located at 31 State Highway 12,
Flemington, New Jersey.  The facility, constituting approximately 4,500 square
feet is occupied under a five-year lease which expires during September 2005.
During fiscal 2002, the Company paid rent of $63,000 plus real estate taxes.
Should this tenancy be terminated for any reason, there is ample comparable
space available in the area for the Company to occupy.  The Company presently
is exploring relocation to larger facilities.

ITEM 3. LEGAL PROCEEDINGS

	The Company is not involved in any legal proceedings.


				  -20-

<PAGE>


ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

	During the fourth quarter of the fiscal year covered by this report,
no matters were submitted to a vote of security holders, though the
solicitation of proxies or otherwise.








				  -21-

<PAGE>


PART II

ITEM 5. MARKET FOR COMMON STOCK AND RELATED SECURITYHOLDER MATTERS

     (a) Market Information.  Since the November 1997 closing of the public
offering, the Company's Common Stock has traded in the over-the-counter
market on the National Association of Securities Dealers, Inc. OTC Bulletin
Board System ("OTC.BB"). Since October 1, 2002, the symbol has been "NVDL".
Prior thereto, the Common Stock traded under the symbol "FLEM". The following
table sets forth the range of high and low closing bid quotations of the
Common Stock as reported by the OTCBB for each fiscal quarter for the past
three fiscal years.  High and low bid quotations represent prices between
dealers without adjustment for retail mark-ups, mark-downs or commissions and
may not necessarily represent actual transactions.


							       Bid  Prices
							   ------------------
							    High         Low
							   ------       -----
FISCAL  2002
---------------------------------------------------------

First Quarter (August 1, 2001 through October 31, 2001)       .60         .43
Second Quarter (November 1, 2001 through January 31, 2002)   2.30         .63
Third Quarter (February 1, 2002 through April 30, 2002)      3.79        2.40
Fourth Quarter (May 1, 2002 through July 31, 2002)           3.62        1.65


FISCAL 2001
---------------------------------------------------------

First Quarter (August 1, 2000 through October 31, 2000)      2.125       .969
Second Quarter (November 1, 2000 through January 31, 2001)   1.562       .438
Third Quarter (February 1, 2001 through April 30, 2001)      1.094       .550
Fourth Quarter (May 1, 2001 through July 31, 2001)            .950       .510


FISCAL  2000
---------------------------------------------------------

First Quarter (August 1, 1999 through October 25, 1999)      1.687       .875
Second Quarter (November 1, 1999 through January 31, 2000)   2.25        .875
Third Quarter (February 1, 2000 through April 30, 2000)      3.375       1.00
Fourth Quarter (May 1, 2000 through July 31, 2000)           1.406       .750




				  -22-

<PAGE>

	The closing bid price of the Company's Common Stock as reported by the
OTCBB was $1.35 on October 21, 2002.

	(b) Holders.  As of October 21, 2002 there were approximately 67
record holders of the Company's Common Stock.

	(c) Dividends.  The Company has never declared or paid a dividend on
its Common Stock, and management expects that all or a substantial portion of
the Company's future earnings will be retained for expansion or development
of the Company's business.  The decision to pay dividends, if any, in the
future is within the discretion of the Board of Directors and will depend
upon the Company's earnings, capital requirements, financial condition and
other relevant factors such as contractual obligations.  Management does not
anticipate that the Company will pay dividends on the Common Stock in the
foreseeable future.  Moreover, there can be no assurance that dividends can
or will ever be paid.

	(d) Recent Sales of Unregistered Securities.   During the fourth
quarter of fiscal 2002, a total of 49,485 shares of the Company's Common Stock
was issued in connection with the cashless exercise of 67,358 warrants.


ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
	RESULTS OF OPERATIONS

General

	Since its inception, substantially all of the Company's revenues have
been derived from consulting activities, primarily in connection with product
development for various pharmaceutical companies. The Company has had a history
of recurring losses from operations, giving rise to an accumulated deficit at
July 31, 2002 of approximately $9,813,000.  Although substantially all of the
Company's revenues to date have been derived from its consulting business, the
future growth and profitability of the Company will be principally dependent
upon its ability to successfully develop its products and to enter into
license agreements with drug companies who will market and distribute the
final products.

	The Company's financial statements have been presented on the basis
that it is a going concern, which contemplates the realization of assets and
the satisfaction of liabilities in the normal course of business.  The Company
incurred losses during the fiscal years ended July 31, 2002 (fiscal 2002) and
2001 (fiscal 2001) and had an accumulated deficit at July 31, 2002 of
approximately $9,813,000.

	The Company's continued existence is dependent upon its ability to
achieve profitable operations or obtain additional financing.  The Company is
currently seeking collaborative arrangements with pharmaceutical companies
for joint development of delivery systems and the successful marketing of
these delivery systems.  In order to pursue this strategy, the Company will
be required to obtain financing and/or consummate a strategic alliance with a
well-funded business partner in the near future.  In view of the Company's
very limited resources, its anticipated expenses (resulting in significant

				  -23-

<PAGE>


operating losses) and the competitive environment in which the Company
operates, there can be no assurance that the Company's operations will be
sustained for the duration of its next fiscal year.

Results of Operations

Fiscal Year 2002 Compared to Fiscal Year 2001

	Consulting revenues for fiscal 2002 increased approximately $39,000
or 13% to $339,000 from $300,000 for fiscal 2001.  This revenue increase for
fiscal 2002 was primarily attributable to an increase in project management
of clinical studies for clients.

	Consulting expenses increased approximately $271,000 or 39% to $962,000
from $691,000 for fiscal 2001.  This increase was due to increased payroll
and inside laboratory expenses.  Selling, general and administrative expenses
increased approximately $2,980,000 or 379% to $3,767,000 from $787,000 for
fiscal 2001.  This increase was due, primarily, to the value of options issued
for services and had no effect on the Company's cash position.

	Total costs and expenses for fiscal 2002 increased approximately
$3,251,000 or 220% to approximately $4,729,000 from approximately $1,478,000
for fiscal 2001.

	This increase includes approximately: $2,208,000 in outside consultant
fees primarily due to options issued to consultants; $288,000 in payroll
expense primarily due to additional employees and the establishment of a
vacation pay accrual; $357,000 in legal & professional fees; $131,000 in bad
debt expense; $92,000 in employee recruiting and relocation; $51,000 in
depreciation and amortization expense due to the earlier purchases of
laboratory equipment;  $40,000 in laboratory expenses due to additional lab
employees; $34,000 in travel expenses;  $28,000 in public company expenses
due primarily to an increase in the number of outside directors and the
increased number of board meetings held during the 2002 Period; $22,000 in
trade show and conference expenses; $19,000 in rent expenses due to increased
rents for the Company's facilities, occupied in October 2000 and the
establishment of the Company's Florida office during October 2001; $19,000 in
insurance expenses due to increased premiums for directors and officers
coverage and additional clinical studies coverage; and, $12,000 in outside
services.


	Decreases in costs and expenses for the 2002 Period, as compared to
the 2001 Period, includes an approximate $71,000 in laboratory testing and
clinical studies costs due primarily to the Company's earlier decision to
establish an internal laboratory.

	A buy-out of a consultant's contract, during the 2002 Period, resulted
in an approximate $32,000 increase in expenses.

	Interest income for fiscal 2002 increased approximately $21,000 or
91% to $44,000 from $23,000 for fiscal 2001.  The interest income increase
was primarily attributable to an increased average cash balance in conjunction
with reduced interest rates for the 2002 year.

	Deferred income tax benefit for fiscal 2002 was approximately $88,000
compared to approximately $47,000 for fiscal 2001.  These benefits resulted
from the sale of the Company's New Jersey net operating losses.

	The resulting net loss for fiscal 2002 was $4,290,000 compared to a
net loss of $1,109,000 for fiscal 2001.


				  -24-

<PAGE>


Liquidity and Capital Resources

	From its inception, the Company's principal sources of capital have
been provided by consulting revenues, private placements and a public offering
of its securities, as well as loans and capital contributions from the
Company's principal stockholders.  At July 31, 2002 the Company had working
capital of approximately $3,095,000 as compared to working capital of $652,000
at July 31, 2001 representing a net increase in working capital of
approximately $2,443,000. During fiscal 2002, the Company successfully closed
an offering of its securities ("Private Placement").  The Private Placement
provided for the sale of approximately 6,667,000 shares of common stock, par
value $.001 per share.  The Company received proceeds, net of offering costs,
of approximately $4,916,000.

	Net cash used in operating activities was approximately $1,871,000 for
fiscal 2002 compared to net cash used in operating activities of approximately
$1,106,000 for fiscal 2001.  Net cash used in operating activities for fiscal
2002 was primarily attributable to the net loss of $4,290,000.  For fiscal
2002, $316,000 was used for investing activities.  Therefore, notwithstanding
a $4,290,000 net loss and $1,109,000 net loss for fiscal 2002 and 2001,
respectively, total cash flow for fiscal 2002 increased approximately
$7,019,000 as compared to a $994,000 increase for fiscal 2001.

	The Company believes that its current cash levels together with
revenues from operations, will be sufficient to satisfy its cash requirements
for the next five (5) months. However, beyond this point there is substantial
doubt about the Company's ability to continue operations without obtaining
additional financing and/or consummating a strategic alliance with a well-
funded business partner.  There are a number of risks and uncertainties
related to the Company's attempt to complete a financing or strategic
partnering arrangement that are outside the control of the Company.  We may
not be able to successfully obtain additional financing on terms acceptable
to the Company, or at all. These uncertainties raise substantial doubt as to
the Company's ability to continue as a going concern. The Company's auditors
have qualified their audit opinion with regard to the Company's ability to
continue as a going concern.


Inflation

	The Company does not believe that inflation has had a material effect
on its results of operations during the past three fiscal years. There can be
no assurance that the Company's business will not be affected by inflation in
the future.

New Accounting Pronouncements

	See Note 1 to the Financial Statements for a discussion of New
Accounting Pronouncements affecting the Company.


ITEM 7. FINANCIAL STATEMENTS

	The response to this item is included as a separate section of this
report commencing on page F-1.


				  -25-

<PAGE>


ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
		ACCOUNTING AND FINANCIAL DISCLOSURE

	Not Applicable.


				PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
	COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT


	The names and ages of  the Directors and Executive Offiers of the
Company are set out below.  All Directors are elected annually, to serve until
the next annual meeting of stockholders and until their successors are duly
elected and qualified.  Officers are elected annually by the Board and serve
at the Board's pleasure.

				   Position with      Principal        Director
Name                        Age    the Company        Occupation         Since
-------------------------------------------------------------------------------
Harry A. Dugger, III, Ph.D. 66     President and      President and      1991
				   Chief Executive    Chief Executive
				   Officer            Officer of the
						      Company

John H. Klein               56     Chairman           Consultant         2002

Robert F. Schaul, Esq.      65     Secretary and      Attorney           1991
				   Director

Jack J. Kornreich           65     Director           Retired            1996

Robert C. Galler            42     Vice President,    Financial          2001
				   Corporate          Advisory
				   Development and    Services
				   Director

Donald J. Deitman           59     Chief Financial    Chief Financial       -
				   Officer            Officer of the
						      Company

Mohammed Abd El-Shafy       49     Vice President,    Vice President        -
				   Formulation        Formulation
				   Development        Development
						      for the Company


Harry A. Dugger, III, Ph.D., President and Director.  Dr. Dugger is a founder
of the Company and has been President and a director of the Company since its
inception in May 1982. Prior to founding the Company, from June 1980 to
November 1982, Dr. Dugger was employed as Vice President of Research and
Development by Bauers-Kray Associates, a company engaged in the development
of pharmaceutical products.  From 1964 to 1980, Dr. Dugger was Associate
Section Head for Research and Development at Sandoz Pharmaceuticals
Corporation.  Dr. Dugger received an MS in Chemistry from the University of
Michigan in 1960 and received a Ph.D. in Chemistry from the University of
Michigan in 1962.

John H. Klein, Chairman of the Board.  Mr. Klein joined NovaDel in February
2002 as a consultant and as Chairman of its Board of Directors.   From April


				  -26-

<PAGE>


1996 to the present Mr. Klein has been affiliated with a number of enterprises,
including True North Capital (Chairman/Managing Director ), Kindred Healthcare
(Director), US Interactive, Inc. (Director), America's Plan (Director and
Chairman), Coleman Co., Inc. (Director), Sunbeam Corp. (Director), Bi Logix,
Inc. (Director), Strategic Business and Technology Solutions, LLC (Chairman),
Cybear (Director and Chairman) and Image Vision (Director and Vice Chairman).
From 1996 to 1998, Mr. Klein  was Chairman and CEO of Mim Corp. From 1989 to
1996 he was President, CEO and Director of Zenith Laboratories, Inc., which
in 1995 merged into IVAX, Inc., of which Mr. Klein  is an Executive
Officer and President of its IVAX North American Multi-Source Pharmaceutical
Group.  Mr. Klein holds BS and MBA degrees from  Roosevelt  University,
Chicago, Illinois. Mr. Klein is a member of the Board's Audit Committee.

Robert F. Schaul, Esq., Secretary and Director.  Mr. Schaul has been a
Director of the Company since November 1991 and was Vice President, Secretary
and General Counsel of the Company from November 1991 to February 1995. He
has advised the Company since its formation.  From 1995 to 1998, Mr. Schaul
was Vice President and General Counsel of Landmark Financial Corp.  From 1989
to 1991, Mr. Schaul was a partner with the law firm of Glynn, Byrnes and
Schaul, and for twenty years prior thereto was an attorney and partner with
the law firm Kerby, Cooper, English, Schaul & Garvin, specializing in business
law and business related litigation. Mr. Schaul received a BA from New York
University in 1961 and a JD from Harvard University in 1964.

Jack J. Kornreich, Director.  Mr. Kornreich has been a director of the Company
since 1996 and is a member of the Board's Audit Committee. He presently acts
as an independent consultant.  From 1989 to 1993, Mr. Kornreich was Executive
Vice President and General Counsel of Bolar Pharmaceutical Corp. (now known
as Watson Pharmaceutical Corp.).  From 1984 to 1989, Mr. Kornreich practiced
law as a partner in the firm of Baum & Kornreich (from 1980 to 1984 the firm
was named Baum, Skigen & Kornreich).  From 1975 to 1984, Mr. Kornreich was in
private practice.  Mr. Kornreich received a JD from Brooklyn Law School in
1963 and an LLM in Corporate Law from New York University in 1975.

Robert C. Galler, Vice President, Corporate Development and Director. Mr.
Galler has been an employee and Director of the Company since September, 2001.
From 1992 to the present, Mr. Galler has been the President and Chairman of
the Lois Joy Galler Foundation for Hemolytic Uremic Syndrom, a non-profit
charity. From 1999 to 2001, Mr. Galler was Vice President, Corporate
Development and Director of  Select Therapeutics, Inc. From 1994 to 1998 Mr.
Galler was a Director and advisor of Synsorb Biotech, Inc. From 1992 to 1994
Mr. Galler was an equity coordinator at Gallers Financial Group, Inc., and
from 1984 to 1992 he was Vice President of Investments with Gruntal & Co.
Mr. Galler attended Hofstra University, Hempstead, N. Y.

Donald Deitman, Chief Financial Officer.  Mr. Deitman joined NovaDel in 1998.
From 1988 until joining NovaDel, Mr. Deitman was employed as a business
consultant implementing multi-module MRP II software systems.  From 1982 to
1988, Mr. Deitman was corporate controller for FCS Industries, Inc. of
Flemington, New Jersey.  From 1975 to 1982, he was manager of materials and
systems for the Walworth Company operations located in Linden and Elizabeth,
NJ and from 1966 to 1975, he was employed by Ortho Pharmaceuticals, Inc. and
Ortho Diagnostics, Inc.  Mr. Deitman received a BS in Accounting from Rutgers
University in 1972.


				  -27-

<PAGE>


Mohammed Abd El-Shafy, Ph.D. Dr. El-Shafy has been an employee of NovaDel
since May of 2002.  He serves as Vice President-Formulation Development.
From 1999 to 2002 he was employed as a Team Leader and Senior Scientist with
Nastech Pharmaceutical Inc., Hauppauge, New York.  From 1998 to 1999 Dr.
El-Shafy was a Post-Doctoral Fellow at the University of Wisconsin's School
of Pharmacy.  He received his doctorate in 1997 from the School of Pharmacy,
University of Wales, Cardiff, Wales, UK. From 1983 to 1993 he was an
Assistant Lecturer of Pharmaceutical Sciences on the Faculty of Pharmacy,
Al-Azhar University, Cairo, Egypt.


Compliance with Section 16(a) of the Securities Exchange Act of 1934

	Section 16(a) of the Exchange Act requires officers, directors and
persons who own more than ten (10) percent of a class of equity securities
registered pursuant to Section 12 of the Exchange Act to file reports of
ownership and changes in ownership with both the SEC and the principal
exchange upon which such securities are traded or quoted.  Officers,
directors and persons holding greater than ten (10) percent of the
outstanding shares of a class of Section 12-registered equity securities
("Reporting Persons") are also required to furnish copies of any such reports
filed pursuant to Section 16(a) of the Exchange Act with the Company.  Based
solely on a review of the copies of such forms furnished to the Company, the
Company believes that from August 1, 2001 to July 31, 2002 all Section 16(a)
filing requirements applicable to its Reporting Persons were complied with.


Compensation of Directors

	The Directors of the Company are elected annually and serve until the
next annual meeting of stockholders and until a successor shall have been duly
elected and qualified.  Effective February 2002, Directors of the Company who
are not employees or consultants receive fees of $1,000 for each meeting of
the Board of Directors or a committee of the Board attended. Such Directors
are also reimbursed for expenses incurred in connection with their attendance
at meetings of the Board of Directors.  Directors may be removed with or
without cause by a vote of the majority of the stockholders then entitled to
vote.  There were no other arrangements pursuant to which any Director was
compensated during fiscal 2002 for any services provided as a Director.

ITEM 10. EXECUTIVE COMPENSATION

			EXECUTIVE COMPENSATION

	The following table sets forth a summary for the fiscal years ended
July 31, 2002, 2001 and 2000, respectively, of the cash and non-cash
compensation awarded, paid or accrued by the Company to the Company's Chief
Executive Officer ("CEO") and its two most highly compensated officers other
than the CEO, who served in such capacities at the end of fiscal 2002
(collectively, the "Named Executive Officers").  No other executive officer
of the Company earned in excess of $100,000 in total annual salary and bonus
for 2000, 2001 and 2002 in all capacities in which such person served the
Company.  There were no restricted stock awards, long-term incentive plan
payouts or other compensation paid during fiscal  2000, 2001 and 2002 to the
Named Executive Officers, except as set forth below:


				  -28-

<PAGE>


SUMMARY COMPENSATION TABLE

<TABLE>
							  Long-Term Compensation
						      ------------------------------
							    Awards           Payouts
						      ---------------------  -------
					      Other               Securities          All
					      Annual  Restricted  underlying          Other
Name and                                      Compen-   Stock     Options/    LTIP    Compen-
Principal            Fiscal  Salary   Bonus   sation    Awards    SAR (1)    Payouts  sation
Position             Year     ($)      ($)      ($)      ($)       (#)         ($)     ($)
-----------------------------------------------------------------------------------------------
<S>                  <C>      <C>     <C>     <C>     <C>         <C>        <C>      <C>

Harry A. Dugger,     2002   347,000    0       0       0             0        0       10,000
 III, Ph.D.                  (2)
 President and CEO
		     2001   182,974    0       0       0             0        0            0

		     2000   226,000    0       0       0        95,000        0            0
		     -----------------------------------------------------------------------

John H. Klein
 Chairman            2002   150,000    0       0       0     1,000,000        0       36,000

		     -----------------------------------------------------------------------

Donald Deitman (2)   2002   104,400    0       0       0             0        0        4,200
 Chief Financial
 Officer             2001    70,800    0       0       0             0        0            0

		     2000    68,000    0       0       0             0        0
		     -----------------------------------------------------------------------

Robert  C. Galler    2000   143,600    0       0       0       700,000        0        6,600
 Vice President
 Corporate
 Development
		     -----------------------------------------------------------------------


</TABLE>


     (1)  No Stock Appreciation Rights have been issued.

     (2)  This amount exceeds the amount of annual compensation payable to
	  Dr. Dugger under his employment agreement.  The reason for this is
	  that during fiscal 2002 Dr. Dugger was paid certain accrued
	  compensation from a prior year.


				  -29-

<PAGE>

		    OPTION GRANTS IN LAST FISCAL YEAR
			   (individual grants)

The following table sets forth information with respect to the Named Executive
Officers concerning grants of options during fiscal 2002:

		   Option/SAR Grants in Last Fiscal Year
			     Individual Grants
-------------------------------------------------------------------------------
       (a)                  (b)           (c)           (d)           (e)

			 Number of     % of Total
			 Securities    Options/SARS
			 Underlying    Granted to     Exercise or
       Name              Options/SARs  Employees in   Base Price   Expiration
			 Granted (#)   Fiscal Year     ($/Sh)         Date
-------------------------------------------------------------------------------
Harry A Dugger III, Ph.D    345,000       16%          $0.70      14 Nov. 2011

John H. Klein             1,000,000       47%          $2.40      31 Jan. 2012

Donald J. Deitman                 0      N/A             N/A           N/A

Robert Galler               350,000       16%          $0.75       4 Dec. 2011
			    350,000       16%          $0.75      11 Dec. 2011


	In September 2001, the Company entered into a short-term employment
agreement with Robert Galler, who was appointed as Vice President - Corporate
Development and a Director.  That agreement provided for the issuance to Mr.
Galler of options to purchase 700,000 shares of our common stock at an
exercise price of $.75 per share.  Under the agreement, the vesting of these
options was subject to the satisfaction of certain conditions precedent. In
December 2001, the agreement with Mr. Galler was amended to recognize the
accomplishment of the conditions.  Among other things, the term was extended
to three years, his compensation was increased, the options became vested,
and he was granted an additional 350,000 options (on the same terms) which
would become vested upon satisfaction of a condition in the amended agreement.

	During November 2001, we cancelled and reissued certain options under
the 1992, 1997 and 1998 Option Plans. An aggregate of 345,000 options were
issued to each of Harry A. Dugger and John J. Moroney at an exercise price
of $.70 per share (110% of the market price), having a term of five years.
An aggregate of 150,000 options were issued to each of Jack Kornreich and
Robert Schaul at an exercise price of $.63 per share (100% of the market
price), having a term of ten years.

	In February 2002, we entered into a consulting agreement with John H.
Klein, who was simultaneously elected as our chairman of the Board.  The
agreement is for a term of one year. Under the agreement, Mr. Klein was
granted options to purchase 1,000,000 shares of our common stock at an
exercise price of $2.40 per share. The options have a term of ten years and
vest in three equal annual installments, beginning in February 2003.


				  -30-

<PAGE>

	Also in February 2002, 187,500 options were issued under the 1998
Option Plan; 37,500 to John J. Moroney, and 75,000 to each of Jack Kornreich
and Robert Schaul. The options have an exercise price of $2.63 per share and
a term of ten years.

	In May 2002, 150,000 non-plan options were issued to Dr. Mohammed
Abd El-Shafy pursuant to an employment agreement. The options have an exercise
price of $3.02 per share, and vest in three equal annual installments.



	    AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
		   AND FISCAL YEAR-END OPTION VALUES

	The following table sets forth information with respect to the Named
Executive Officers concerning the exercises of options during fiscal 2002 and
the number and value of unexercised options held as of the end of fiscal 2002.


					 Number of
					 Securities         Value of
					 Underlying         Unexercised
					 Unexercised        in-the
		    Number of            Options            Money Options
		    Shares               at Fiscal          at Fiscal
Name of             Acquired    value    Year End;          Year End ($);
Executive           on         Realized  (Exercisable/      (Exercisable
Officer             Exercise     ($)     Unexercisable)     Unexercisable)
-----------------------------------------------------------------------------
Harry A. Dugger,
 III, Ph.D.           0             -    645,000 / 0        345,000 / 0

John H. Klein         0             -    0 / 1,000,000            0 / 0

Robert C. Galler      0             -    700,000 / 0        665,000 / 0

Donald Deitman        0             -              -                  -



Employment Agreements and Change in Control Arrangements

	Dr. Dugger.  In February 2002, effective January 1, 2002, Dr. Dugger
entered into a new three-year employment agreement at a base salary, for the
first year, of $248,500 per year (which increases each year by the greater
of the CPI index or 5%).  Except for the increase in base salary, there was
no material difference between the new employment agreement and that
previously in effect.

	John Klein.  In February 2002, Mr. Klein entered into a one-year
consulting agreement at a base compensation of $300,000, plus certain fringe
benefits of approximately $72,000 per year.  Pursuant to the agreement, he
was granted 1,000,000 non-plan options at $2.40 per share.  See "Certain
relationships and related transactions."  In addition, Mr. Klein is entitled
to certain success fees upon completion of corporate deals he introduces to
NovaDel.

	Robert C. Galler. In December 2001, we entered into a three year
employment agreement with Mr. Galler, who was appointed Vice President -
Corporate Development and elected to the Board of Directors.  Pursuant to the
agreement, he receives a base salary of $180,000 per year.  In addition, he
was granted 1,050,000 non-plan options at $.75 per share.  See "Certain
relationships and related transactions."


				  -31-

<PAGE>

	Donald Deitman. In February 2002, effective January 1, 2002, Mr.
Deitman entered into a three year employment agreement as our Chief Financial
Officer. The agreement provides for a base salary, for the first year, of
$125,000 per year (which increases each year by the greater of the CPI index
or 5%).  All other provisions of the agreement are the same as those in effect
for our other executives.

	Mohammed Abd El-Shafy, Ph.D.  In May 2002, we entered into a three
year employment agreement with Dr. El-Shafy, who was appointed Vice President-
Formulation Development.  Pursuant to the agreement, he receives a base salary,
for the first year, of $110,000 (which increases each year by the greater of
the CPI index or 5%).  In addition, he was granted 150,000 non-plan options
at $3.02 per share.

	The foregoing agreements also provide for certain non-competition and
non-disclosure covenants on the part of such executive.  However, with respect
to the non-competition covenants, a court may determine not to enforce such
provisions or only partially enforce such provisions.  Additionally, each of
the foregoing agreements (other than John Klein) provides for certain fringe
benefits, such as inclusion in pension, profit sharing, stock option, savings,
hospitalization and other benefit plans at such times as NovaDel shall adopt
them.


Stock Option Plans

	 NovaDel has three stock option plans, adopted in 1992, 1997 and 1998,
respectively (collectively referred to as the "Plans").  The 1992 and 1997
Plans provides for the issuance of options to purchase 500,000 shares of
common stock, and the 1998 Plan provides for the issuance of options to
purchase 1,075,000 shares of common stock, for a total of 2,075,000 shares.
The 1997 Stock Option Plan is administered by Harry A. Dugger, III, Ph.D.
and John Klein (as of March 27, 2002), who constitute the Compensation
Committee of the Board of Directors ("Committee"), and the 1992 Stock Option
Plan and 1998 Stock Option Plan are administered by the entire Board of
Directors.  For purposes of the following discussion, the term "Committee"
will be used to reference the Committee with respect to the 1997 Stock Option
Plan and the entire Board of Directors with respect to the 1992 Stock Option
Plan and 1998 Stock Option Plan, as applicable.  The Committee has sole
discretion and authority, consistent with the provisions of the Plans, to
select the Eligible Participants to whom options will be granted under the
Plans, the number of shares which will be covered by each option and the form
and terms of the agreement to be used.  All employees and officers of the
Company are eligible to participate in the Plans.

	At July 31, 2002, 500,000, 500,000 and 787,500 shares of our common
stock was reserved for issuance pursuant to the 1992, 1997 and 1998 Plans,
respectively.  The exercise prices for the outstanding options reserved under
the 1992 Plan range between $.63 and $2.00 per share; the exercise prices for
the outstanding options reserved under the 1997 Plan range between $.63 and
$2.00 per share; and the exercise prices for the outstanding options reserved
under the 1998 Plan range between $.63 and $2.63 per share.

	The Committee is empowered to determine the exercise price of options
granted under the Plans, but the exercise price of ISOs must be equal to or
greater than the fair market value of a share of common stock on the date

				  -32-

<PAGE>


the option is granted (110% with respect to optionees who own at least 10% of
the outstanding common stock).  The Committee has the authority to determine
the time or times at which options granted under the Plans become exercisable,
but options expire no later than ten years from the date of grant (five years
with respect to Optionees who own at least 10% of the outstanding common stock
of NovaDel).  Options are nontransferable, other than by will and the laws of
descent, and generally may be exercised only by an employee while employed by
NovaDel or within 90 days after termination of employment (one year from
termination resulting from death or disability).

	No ISO may be granted to an employee if, as the result of such grant,
the aggregate fair market value (determined at the time each option was
granted) of the shares with respect to which ISOs are exercisable for the
first time by such employee during any calendar year (under all such plans of
NovaDel and any parent and subsidiary) exceeds $100,000.  The Plans do not
confer upon any employee any right with respect to the continuation of
employment by NovaDel, nor do the Plans interfere in any way with the
employee's right or NovaDel's right to terminate the employee's employment at
any time.


Non-Plan Options

	As of July 31, 2002, we had 2,700,000 non-plan options outstanding as
follows:  600,000 options exercisable at $1.84 per share; 700,000 options
exercisable at $.75 per share; 1,000,000 options exercisable at $2.40 per
share; 250,000 options exercisable at $3.18 per share; and 150,000 options
exercisable at $3.02 per share.


Compensation Committee Interlocks and Insider Participation

	Harry A. Dugger, III and John H. Klein serve as the members of the
Company's Compensation Committee, which reviews and makes recommendations
with respect to compensation of officers, employees and consultants, including
the granting of options under the Company's 1997 Stock Option Plan.  The 1992
and 1998 Stock Option Plans are administered by the entire Board.  In the case
of a conflict, Mr. Kornreich replaces the conflicted Compensation Committee
member.

	Robert F. Schaul, a Director and Secretary of the Company, earned
legal fees from the Company during fiscal 2002 in the approximate amount of
$125,000.  See "Certain Transactions--Legal Fees," below.



ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information, as of July 31, 2002 with respect
to the beneficial ownership of the outstanding shares of our common stock
(14,441,052 as of such date plus, where relevant for particular beneficial
owners, shares which such beneficial owner has the right to acquire), by
(i) any holder known to us owning more than five percent (5%) of the
outstanding shares; (ii) our officers and directors; and (iii) the directors
and officers of NovaDel as a group:


Name of                       No. of Shares
Beneficial                    of Common                  Percentage of
Owner (1)                     Stock                      Class
------------------------------------------------------------------------

Harry A. Dugger, III, Ph.D.   1,829,003(3)               12.12%

John Klein                            0(4)                 ---

Donald Deitman                        0                    ---

Robert C. Galler                700,000(5)                4.62%

Robert F. Schaul, Esq.          264,310(6)                1.80%

Jack J. Kornreich, Esq.         244,000(6)                1.67%

Mohammed Abd El-Shafy                 0(7)                 ---

Lindsay A. Rosenwald         13,233,334(8)               62.84%

Biomedical Investment
 Group, LLC                   5,333,334(8)(9)            31.18%

All Executive Officers and
 Directors as a group
 (7 persons)                  3,037,599(3)(4)(5)(6)(7)   20.21%



 (1)    The address of all holders listed herein is c/o NovaDel Pharma Inc.,
31 State Highway 12, Flemington, New Jersey 08822.

 (2)    Except as otherwise indicated, each named holder has, to our knowledge,
sole voting and investment power with respect to the shares indicated.
Beneficial ownership as reported in the table above has been determined in
accordance with Instruction (4) to Item 403 of Regulation S-B of the Exchange
Act.

 (3)    Includes options to purchase 200,000 shares of common stock
(exercisable at $.70 per share) issued under the 1992 Stock Option Plan which
expire in July 2006; options to purchase 50,000 shares of common stock
(exercisable at $.70 per share) under the 1997 Stock Option Plan which expire
in December 2006; options to purchase 95,000 shares of common stock
(exercisable at $.70 per share) issued under the 1998 Stock Option Plan which
expire in January 2005, options to purchase 300,000 shares of common stock
issued outside of the Plans (exercisable at $1.84 per share) which expire
November 2007; 108,000 shares owned by his daughter Christina Dugger Sommers;
and 108,000 shares owned by his son Andrew Dugger.  Dr. Dugger may be deemed
to be a "parent" of the Company as such term is defined under the Federal
securities laws.

 (4)    Does not include Non-Plan options, issued in February 2002, to
purchase 1,000,000 shares of common stock at an exercise price of $2.40 per
share. These options vest in three equal annual installments, beginning in
2003, and expire in January 2012.


				  -34-

<PAGE>


 (5)     Mr. Galler was granted Non-Plan options to purchase 1,050,000 shares
of common stock, at an exercise price of $0.75 per share. 700,000 of these
options are vested; the remaining 350,000 options are subject to a condition
precedent which has not yet been met. The vested options expire in September
2011.

 (6)     Includes: 20,000 options, issued under the 1992 Option Plan, to
purchase common stock at an exercise price of $.63 per share, expiring in
July, 2006; 25,000 options issued under the 1997 Option Plan, to purchase
common stock at an exercise price of $.63 per share, expiring in March 2008;
10,000 options issued under the 1998 Option Plan, to purchase common stock
at an exercise price of $.63 per share, expiring in September 2009: 95,000
options issued under the 1998 Option Plan, to purchase common stock at an
exercise price of $.63 per share, expiring in January 2010; and 75,000 options
issued under the 1998 Option Plan, to purchase common stock at an exercise
price of $2.63 per share, expiring in February 2012.

 (7)     Does not include Non-Plan options, issued in May 2002, to purchase
150,000 shares of common stock at an exercise price of $3.02 per share.  The
options vest equally in November 2002, May 2003 and May 2004 and expire in
May 2012.

 (8)     Includes 3,950,000 shares of common stock and warrants to purchase
3,950,000 shares of common stock at an exercise price of $.75 per share which
expire in December 2008.  Also includes 2,666,667 shares of common stock and
2,666,667 warrants to purchase 2,666,667 shares of common stock, which expire
in March 2009,  owned by Biomedical Investment Group, LLC which is a limited
liability company wholly owned by Lindsay A. Rosenwald

 (9)     Includes warrants to purchase 2,666,667 shares of common stock at an
exercise price of $.75 per share which expire in March 2009.


The following table sets forth information regarding securities authorized
for issuance as of the end of fiscal 2002 with respect to compensation we
exchanged for consideration in the form of services.


		    Equity Compensation Plan Information


		      Number of
		      securities         Weighted average       Number of
		     to be issued        exercise price         securities
		   upon exercise of       of outstanding        remaining
		  outstanding options,   options,warrants      available for
Plan Category     warrants and rights       and rights        future issuance
------------------------------------------------------------------------------
			  (a)                  (b)                   (c)
		   -----------------------------------------------------------
Equity compensation
 plans approved by
 security holders               0              N/A                   N/A

Equity compensation
 plans not approved
 by security holders    3,717,472           $1.658                   N/A
		    ----------------------------------------------------------
TOTAL                   3,717,472           $1.658                   N/A
		    ==========================================================


				  -35-


<PAGE>


ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

	To the best of management's knowledge, other than as set forth below,
there were no material transactions, or series of similar transactions, or
any currently proposed transactions, or series of similar transactions, to
which NovaDel was or is to be a party, in which the amount involved exceeds
$60,000, and in which any director or executive officer, or any security
holder who is known by us to own of record or beneficially more than 5% of
any class of our common stock, or any member of the immediate family of any
of the foregoing persons, has an interest.

	During fiscal 2002 we paid Mr. Schaul $125,000 for legal services
rendered to us.

	In fiscal 1998, we lent the principal amount of $60,000 to Dr. Dugger
in exchange for a 7% promissory note.  The note was due on demand, with
interest payable quarterly.  This note was paid in full in January 2002.

	In September 2001, the Company entered into a short-term employment
agreement with Robert Galler, who was appointed as Vice President - Corporate
Development and a Director.  That agreement provided for the issuance to Mr.
Galler of options to purchase 700,000 shares of our common stock at an
exercise price of $.75 per share.  Under the agreement, the vesting of these
options was subject to the satisfaction of certain conditions precedent.  In
December 2001, the agreement with Mr. Galler was amended to recognize the
accomplishment of the conditions.  Among other things, the term was extended
to three years, his compensation was increased, the options became vested,
and he was granted an additional 350,000 options (on the same terms) which
would become vested upon satisfaction of a condition in the amended agreement.

	During November 2001, we cancelled and reissued certain options under
the 1992, 1997 and 1998 Option Plans. An aggregate of 345,000 options were
issued to each of Harry A. Dugger and John J. Moroney at an exercise price of
$.70 per share (110% of the market price), having a term of five years. An
aggregate of 150,000 options were issued to each of Jack Kornreich and Robert
Schaul at an exercise price of $.63 per share (100% of the market price),
having a term of ten years.

	During December 2001, we received net proceeds of approximately
$3,000,000 from a private placement of 4,000,000 units, which were purchased
by Lindsay Rosenwald.  Each unit consisted of one share of common stock, and
a warrant (which expires December 2008) to purchase an additional share of
our common stock at an exercise price of $.75.  As part of the placement
agreement, the company agreed to elect to the Company's Board a Director to
be nominated by Dr. Rosenwald (as of this Report, no such nominee had been
selected) and to permit Dr. Rosenwald or a representative of his to attend
Board meetings.  Appropriate confidentiality agreements are in place to
protect confidential company information.. In March 2002, we received net
proceeds of approximately $2,000,000 from a private placement of 2,666,667
additional units at a sale price of $.75 per unit.  These units were purchased
by Biomedical Investment Group LLC, which is affiliated with Dr. Rosenwald.
These warrants expire in March 2009.


				  -36-

<PAGE>

	In February 2002, we entered into a consulting agreement with John H.
Klein, who was simultaneously elected as our chairman of the Board.  The
agreement is for a term of one year. Under the agreement, Mr. Klein was
granted options to purchase 1,000,000 shares of our common stock at an
exercise price of $2.40 per share. The options have a term of ten years and
vest in three equal annual installments, beginning in February 2003.

	Also in February 2002, 187,500 options were issued under the 1998
Option Plan; 37,500 to John J. Moroney, and 75,000 to each of Jack Kornreich
and Robert Schaul. The options have an exercise price of $2.63 per share and
a term of ten years.


Legal Fees

	During fiscal 2002 the Company paid Mr. Schaul approximately $125,000
for legal services rendered to the Company.





				  PART IV

ITEM 13. EXHIBITS LIST AND REPORTS ON FORM 8-K

     (a) (1) The following financial statements are included in Part II,
	     Item 7:

	     Report of Independent Auditors                 Page F-1
	     Balance Sheet                                       F-2
	     Statements of Operations                            F-3
	     Statements of Changes in Stockholders' Equity       F-4
	     Statements of Cash Flows                            F-5
	     Notes to Financial Statements                       F-6











				  -37-

<PAGE>



	(a) (2) List of Exhibits


	Incorporated Documents                      SEC Exhibit Reference
---------------------------------------------------------------------------
2.1     Agreement of Merger dated as of      As filed with the Registrant's
	October 29, 1998                     Preliminary  Proxy Statement on
					     October 20, 1998,
					     File No. 000-23399

3.1     Certificate of Incorporation of      As filed with the Registrant's
	the Registrant, as amended           Form SB-2, on August 8, 1997,
					     File No. 333-33201

3.2     Bylaws of the Registrant, as amended As filed with the Registrant's
					     Form SB-2, on August 8, 1997,
					     File No. 333-33201

4.1     Form of Warrant Agreement            As filed with the Registrant's
					     Form SB-2, on October 31, 1997,
					     File No. 333-33201

4.3     Form of Class A Warrant Certificate  As filed with the Registrant's
					     Form SB-2, on October 31, 1997,
					     File No. 333-33201

4.4     Form of Underwriters' Option         As filed with the Registrant's
	 Agreement                           Form SB-2, on October 31, 1997,
					     File No. 333-33201

10.1    Employment Agreement with Harry      As filed with the Registrant's
	 A. Dugger, III, Ph.D.               Form SB-2, on August 8, 1997,
					     File No. 333-33201

10.2    Employment Agreement with John J.    As filed with the Registrant's
	 Moroney                             Form SB-2, on October 3, 1997,
					     File No. 333-33201

10.3    Agreement dated December 7, 1996     As filed with the Registrant's
	between the Registrant and Altana,   Form SB-2, on August 8, 1997,
	Inc.                                 File No. 333-33201

10.4    Registrant's 1992 Stock Option Plan  As filed with the Registrant's
					     Form SB-2, on August 8, 1997,
					     File No. 333-33201

10.5    Form of Option Agreement under the   As filed with the Registrant's
	1992 Stock Option Plan               Form SB-2, on October 3, 1997,
					     File No. 333-33201

10.6    Registrant's 1997 Stock Option Plan  As filed with the Registrant's
					     Form SB-2, on August 8, 1997,
					     File No. 333-33201

10.7    Form of Option Agreement under the   As filed with the Registrant's
	1997 Stock Option Plan               Form SB-2, on October 3, 1997,
					     File No. 333-33201

10.8    Agreement with Rapid Spray           As filed with the Registrant's
	(Clemastine) Dated June 2, 1992      Form SB-2 Dated August 8, 1997,
					     File No. 333-33201

10.9    Agreement with Rapid Spray           As filed with the Registrant's
	(Nitroglycerin) dated June 2, 1992   Form SB-2, on August 8, 1997,
					     File No. 333-33201

10.10   Agreement with Creative Technologies,As filed with the Registrant's
	Inc. dated December 26, 1996         Form SB-2, on October 3, 1997,
					     File No. 333-33201

10.11   Registrant's 1998 Stock Option Plan  As filed with the Registrant's
					     Preliminary Proxy Statement on
					     October 20, 1998, File No.
					     000-23399

				  -38-

<PAGE>


10.12   Employment Agreement with Donald P.  As filed with the Registrant's
	Cox, Ph.D.                           Form 10-KSB on October 28, 1999,
					     File No. 000-23399

10.13   Employment Agreement with Kenneth    As filed with the Registrant's
	Cleaver, Ph.D.                       Form 10-KSB on October 28, 1999,
					     File No. 000-23399

10.14   Amendment to Consulting Agreement    As filed with the Registrant's
	with Saggi Capital Corp. dated       Form 10-KSB on October 28, 1999
	March 25, 1998                       File No. 000-23399

10.15   Agreement with Altana, Inc., dated   As filed with the Registrant's
	December 7, 1996                     Form 10-KSB/A on September 26,
					     2001, File No. 000-23399

10.16   Agreement with CLL Pharma dated      As filed with the Registrant's
	February 12, 1998                    Form 10-KSB/A on September 26,
					     2001, File No. 000-23399

10.17   Agreement with Nace Resources, Inc., As filed with the Registrant's
	dated December 29, 1997, together    Form 10-KSB/A on September 26,
	with Amendment Number 1 dated        2001, File No. 000-23399
	February 9, 1998; Amendment Number
	2 dated November 29, 1999; and,
	Amendment Number 3, dated May 5,
	2000


10.18   Agreement with PolyMASC              As filed with the Registrant's
	Pharmaceuticals plc, dated July 25,  Form 10-KSB/A on September 26,
	2000                                 2001, File No. 000-23399

10.19   Authorization to proceed with        As filed with the Registrant's
	Innovex, Inc. and Novartis           Form 10-KSB/A on September 26,
	Pharmaceuticals Corp., dated         2001, File No. 000-23399
	June 15, 2000

10.20   Consulting Agreement with John Klein As filed with the Registrant's
					     Form SB-2, on April 15,2002,
					     File No. 333-86262

10.21   Employment Agreement with Robert     As filed with the Registrant's
	Galler.                              Form SB-2, on April 15,2002,
					     File No. 333-86262

10.22   Employment Agreement Amendment No.   As filed with the Registrant's
	1 with Robert Galler                 Form SB-2, on April 15,2002,
					     File No. 333-86262

10.23   Employment Agreement with Donald     As filed with the Registrant's
	Deitman.                             Form SB-2, on April 15,2002,
					     File No. 333-86262

10.24   Common Stock and Warrant Purchase    As filed with the Registrant's
	Agreement dated December 12, 2001.   Incorporated by Reference to
					     Schedule 13D filed on December
					     21, 2001 by Lindsay A. Rosenwald,
					     M.D.

10.25   Amendment No. 1 to Common Stock and  As filed with the Registrant's
	Warrant Purchase Agreement           Form SB-2, on April 15,2002,
					     File No. 333-86262

10.26   Employment Agreement with Mohammed   As filed with the Registrant's
	Abd El-Shafy, Phd.                   Form SB-2, Amendment #2, on
					     September 3, 2002,
					     File No. 333-86262



				  -39-

<PAGE>


11.1    *  Computation of earnings per share

23.1    *  Consent of Wiss & Company, LLP

99.1    *  Certification of Chief Executive Officer and Chief Financial
	   Officer



	*   Filed herewith


	(b) Reports on Form 8-K

	    No reports on Form 8-K were filed during the last quarter of
	    fiscal 2002.




ITEM 14. CONTROLS AND PROCEDURES

	Within the 90-day period prior to the date of this report, our Chief
Executive Officer and Chief Financial Officer performed an evaluation of our
disclosure controls and procedures, which have been designed to permit us to
effectively identify and timely disclose important information.  They concluded
that the controls and procedures were effective.  Since the date of the
evaluation, we have made no significant changes in our internal controls or
in other factors that could significantly affect our internal controls.








				  -40-



<PAGE>


		       INDEPENDENT AUDITORS' REPORT


To the Audit Committee of
 NOVADEL PHARMA INC.


We have audited the balance sheet of NOVADEL PHARMA INC. (formerly known as
Flemington Pharmaceutical Corporation) as of July 31, 2002 and the related
statements of operations, changes in stockholders' equity and cash flows for
each of the two years in the period then ended.  These financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of NOVADEL PHARMA INC. at
July 31, 2002, and the results of its operations and its cash flows for each
of the two years in the period then ended are in conformity with accounting
principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.  As discussed in Note 2 to the
financial statements, the Company has had a recent history of recurring
losses from operations, giving rise to an accumulated deficit through July
31, 2002 and is currently developing pharmaceutical products which will
require substantial financing to fund anticipated product development costs.
Resulting operating losses and negative cash flows from operations are likely
to occur until, if ever, profitability can be achieved through successful
marketing of newly developed products.  These factors raise substantial doubt
about the Company's ability to continue as a going concern.  Management's
plans in regard to these matters are described in Note 2.  The financial
statements do not include any adjustments that might result from the outcome
of this uncertainty.


						    WISS & COMPANY, LLP


Livingston, New Jersey
October 17, 2002

				  F-1


<PAGE>

			    NOVADEL PHARMA INC.
	     (Formerly Flemington Pharmaceutical Corporation)

			      BALANCE SHEET
			      JULY 31, 2002

	 ASSETS

CURRENT ASSETS:
 Cash and equivalents......................  $3,314,000
 Accounts receivable - trade, less
  allowance for doubtful accounts
  of  $88,000..............................       1,000
 Prepaid expenses and other current assets.      96,000
					      ---------
 Total Current Assets......................              $3,411,000

FURNITURE, FIXTURES, EQUIPMENT
 and LEASEHOLD IMPROVEMENTS, LESS
 ACCUMULATED DEPRECIATION OF $172,000......                 406,000

OTHER ASSETS                                                 22,000
							  ---------
							 $3,839,000
							  =========

	 LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
 Accounts payable-trade....................    $125,000
 Accrued expenses and other current
  liabilities..............................     191,000
						-------
 Total Current Liabilities.................              $  316,000


COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY :
 Preferred stock, $.01 per value:
  Authorized 1,000,000 shares, none issued
 Common stock $.001 par value:
  Authorized - 50,000,000 shares............
   Issued and outstanding -
   14,448,817 shares .......................     14,000
 Additional paid-in capital................. 13,322,000
 Accumulated Deficit........................ (9,813,000)
					     ----------
 Total Stockholders' Equity ................              3,523,000
							  ---------
							 $3,839,000
							  =========
See accompanying notes to financial statements.



				 F-2

<PAGE>



			   NOVADEL PHARMA INC.
	    (Formerly Flemington Pharmaceutical Corporation)

			STATEMENTS OF OPERATIONS


						 Year Ended
						  July 31,
					    ---------------------
					       2002        2001
					    ----------   ----------

CONSULTING REVENUES.....................   $   339,000  $   300,000

CONSULTING EXPENSES.....................       962,000      691,000

SELLING, GENERAL AND ADMINISTRATIVE
 EXPENSES...............................     3,767,000      787,000
					     ---------    ---------
LOSS FROM OPERATIONS....................    (4,390,000)  (1,178,000)

BUY-OUT OF CONSULTANT'S CONTRACT........       (32,000)           -

INTEREST INCOME.........................        44,000       23,000
					     ---------    ---------
NET LOSS BEFORE TAXES...................    (4,378,000)  (1,155,000)

DEFERRED INCOME TAX BENEFIT.............        88,000       46,000
					     ---------    ---------
NET LOSS................................   $(4,290,000) $(1,109,000)
					     =========    =========

BASIC AND DILUTED LOSS
 PER COMMON SHARE:
 Net Loss...............................   $      (.38) $      (.18)
					    ==========   ==========
WEIGHTED AVERAGE NUMBER OF COMMON
 SHARES OUTSTANDING.....................    11,361,000    6,326,000
					    ==========   ==========



See accompanying notes to financial statements.


				    F-3

<PAGE>


			     NOVADEL PHARMA INC.
	      (Formerly Flemington Pharmaceutical Corporation)

		STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY



		      Common Stock
		    ----------------
				       Additional
			     Par        Paid-in      Accumulated  Stockholders'
		     Shares  Value      Capital        Deficit       Equity
-------------------------------------------------------------------------------
BALANCE,
 JULY 31, 2000    5,877,300  $ 6,000  $ 5,250,000   $(4,414,000)   $   842,000
		  -------------------------------------------------------------
YEAR ENDED
 JULY 31, 2001
 Common Shares
  Issued for
  Services            3,937        -        6,000             -          6,000
 In connection
  with private
  placement,
  net of costs    1,843,663    2,000    1,155,000             -      1,157,000
 Net Loss                 -        -            -    (1,109,000)    (1,109,000)
		  ------------------------------------------------------------
BALANCE,
 JULY 31, 2001    7,724,900  $ 8,000  $ 6,411,000   $(5,523,000)   $   896,000
		  ------------------------------------------------------------

YEAR ENDED
 JULY 31, 2002
 Common Shares
  Issued in
  connection with
  private
  placements,
  net of costs    6,666,667    6,000    4,910,000             -      4,916,000
 Shares issued
  for Options
  exercised           7,765        -            -             -              -
 Shares issued
  for Warrants
  exercised          49,485        -            -             -              -
 Options issued
  for services            -        -    1,947,000             -      1,947,000
 Warrants issued
  for services            -        -       54,000             -         54,000
 Net Loss                 -        -            -    (4,290,000)    (4,290,000)
		 -------------------------------------------------------------
BALANCE,
 JULY 31, 2002   14,448,817  $14,000  $13,322,000   $(9,813,000)   $ 3,523,000
		 =============================================================







See accompanying notes to financial statements.


				     F-4



			       NOVADEL PHARMA INC
		(Formerly Flemington Pharmaceutical Corporation)

			    STATEMENTS OF CASH FLOWS


						      Year Ended
						       July 31,
						-----------------------
						   2002           2001
CASH FLOW FROM OPERATING ACTIVITIES:             --------       -------
 Net  loss                                     $(4,290,000)   $(1,109,000)
 Adjustments to reconcile net loss to
  net cash flows from operating activities:
  Shares issued for services                             -          6,000
  Options issued for services                    1,947,000              -
  Warrants issued for services                      54,000              -
  Depreciation and amortization                     77,000         24,000
  Allowances for Doubtful Accounts                  79,000              -
  Changes in operating assets and liabilities:
   Accounts receivable                              12,000        (46,000)
   Due from D&O Insurance Carrier                        -         86,000
   Demand note receivable, Officer                  60,000              -
   Prepaid expenses and other current assets       (39,000)        (5,000)
   Due from Joint Venture partner for
    reimbursable expenses                            6,000         74,000
   Other Assets                                     (5,000)        (7,000)
   Accounts payable - trade                        114,000        (57,000)
   Billings in excess of costs and estimated
    earnings on uncompleted contracts                    -        (49,000)
   Accrued expenses and other current liabilities  114,000        (23,000)
						 ---------      ----------
Net cash flows from operating activities        (1,871,000)    (1,106,000)
						 ---------      ---------

CASH FLOWS FROM INVESTING ACTIVITIES -
 Purchase of property and equipment               (316,000)      (166,000)
						 ---------      ---------
Net cash flows from investing activities          (316,000)      (166,000)
						 ---------      ---------

CASH FLOWS FROM FINANCING ACTIVITIES -
 Proceeds received from private placements       4,916,000      1,157,000
						 ---------      ---------
Net cash flows from financing activities         4,916,000      1,157,000
						 ---------      ---------

NET CHANGE IN CASH                               2,729,000       (115,000)

CASH,  BEGINNING OF YEAR                           585,000        700,000
						 ---------      ---------
CASH,  END OF YEAR                              $3,314,000     $  585,000
						 =========      =========


SUPPLEMENTAL CASH FLOW INFORMATION:
 Interest paid                                  $        -     $        -
						 =========      =========
 Income taxes paid
						$        -     $        -
						 =========      =========


See accompanying notes to financial statements.



				     F-5

<PAGE>



			      NOVADEL PHARMA INC.
	       (Formerly Flemington Pharmaceutical Corporation)

			 NOTES TO FINANCIAL STATEMENTS

Note 1 - Nature of the Business and Summary of Significant Accounting Policies:

Nature of the Business - NOVADEL PHARMA INC. (the "Company"), which was
formerly known as Flemington Pharmaceutical Corporation, is incorporated in
the State of Delaware.  The Company is engaged in domestic and international
consulting activities and the development of novel pharmaceutical products
combining presently marketed drugs with innovative patent-pending oral dosage
delivery systems of the Company, designed to enhance and accelerate the onset
of the therapeutic benefits which the drugs are intended to produce.
Management intends to develop the products in collaboration with
pharmaceutical companies having significant existing sales of the
pharmaceutical compounds being incorporated into the Company's dosage
delivery systems, thereby creating a more effective and more attractive
product.

	Revenues and Costs - Revenues from contract clinical research are
	recognized as earned.

	Contract costs normally consist of fees paid to outside clinics for
	studies and an allocable portion of the Company's operating expenses.
	General and administrative costs pertaining to contracts are charged
	to expense as incurred.

	Cash Equivalents - Cash equivalents include certificates of deposit
	and money market instruments purchased with original maturities of
	three months or less.

	Financial Instruments - Financial instruments include cash and cash
	equivalents, accounts receivable, amounts due from joint venture
	partner and insurance carrier, loans to stockholders, accounts payable,
	and accrued expenses.  The amounts reported for financial instruments
	are considered to be reasonable approximations of their fair values,
	based on market information available to management.

	Furniture, Fixtures and Equipment - Furniture, fixtures and equipment
	are stated at cost.  The Company provides for depreciation using
	accelerated methods, based upon estimated useful lives of 5 to 7 years
	for furniture, fixtures and equipment.

	Income Taxes - Temporary differences between financial statement and
	income tax reporting result primarily from net operating losses. As
	a result of these temporary differences, the Company has recorded a
	deferred tax asset with an offsetting valuation allowance for the
	same amount.

	Defined Contribution Retirement Plans - The Company has a Simple IRA
	retirement plan providing for contributions at management's discretion.
	During the years ended July 2002 and July 2001, the Company made
	contributions to the retirement plan of approximately $11,000 and
	approximately $15,000, respectively.

	Risk Concentrations:

	(a) Credit Risk -  The Company maintains its cash balances in
	    financial institutions that are insured by the Federal Deposit
	    Insurance Corporation (FDIC) up to $100,000 each.  Such balances,
	    at times, may exceed the FDIC limits.

	(b) Major Customers - During fiscal 2002, the Company had revenue
	    from two customers located in the USA approximating 46% and 40%,
	    respectively, of the Company's total revenue.

	    During fiscal 2001, the Company had  revenue from two customers
	    located in the United States approximating 40 % and 18 %,
	    respectively, of the Company's total revenue.

					F-6

<PAGE>

	(c) Supplier Dependence - The Company believes that certain raw
	    materials, including inactive ingredients, are available only
	    from a limited number of suppliers internationally and that
	    certain packaging materials intended for use in connection with
	    its spray products currently are available from limited supply
	    sources.  The Company does not believe it will encounter
	    difficulties in obtaining inactive ingredients or packaging
	    materials necessary for the manufacture of its products.
	    However, there can be no assurance that the Company will be able
	    to enter into satisfactory purchasing agreements or arrangements,
	    thereby, causing a potential significant adverse effect on the
	    Company's ability to arrange for the manufacture of formulated
	    products.

	Use of Estimates - The preparation of financial statements in
	conformity with generally accepted accounting principles requires
	management to make estimates and assumptions that affect the reported
	amounts of assets and liabilities and disclosures of contingent assets
	and liabilities at the date of the financial statements and the
	reported amounts of revenues and expenses during the reporting period.
	Actual results could differ from those estimates.

	Earnings (Loss) per Share - Statement of Financial Accounting Standards
	(SFAS) No. 128, "Earnings Per Share" requires the disclosure of both
	diluted and basic earnings per share.  Basic earnings per share is
	based on the weighted average of all common shares outstanding.  The
	computation of diluted earnings per share does not assume the
	conversion, exercise or contingent issuance of securities that would
	have an antidilutive effect on earnings per share.

	Recent Accounting Pronouncements - In August 2001, the FASB issued,
	SFAS No. 143, Accounting for Asset Retirement Obligations, which
	requires companies to record a liability at fair value for asset
	retirement obligations in the period in which they are incurred.  The
	associated asset retirement costs are capitalized as part of the
	carrying amount of the long-lived asset.  This Statement is effective
	for the Company for the fiscal year beginning June 1, 2003.  The Company
	is currently evaluating the provisions of this Statement, but does not
	believe adoption of the statement will result in material impact to its
	results of operations or financial position. In October 2001, the FASB
	issued SFAS No. 144, Accounting for the Impairment or Disposal of
	Long-Lived Assets, which provides a single accounting model for long-
	lived assets to be disposed of.  This Statement is effective for the
	Company for the fiscal year beginning August 1, 2002.  The Company
	is currently evaluating the provisions of this Statement, but does
	not anticipate that adoption will result in a material impact to its
	results of operations or financial position.

Note 2 - Management's Plans to Overcome Operating and Liquidity Difficulties

	The Company's financial statements have been presented on the basis
	that it is a going concern, which contemplates the realization of
	assets and the satisfaction of liabilities in the normal course of
	business.

	The Company's continued existence is dependent upon its ability to
	achieve profitable operations or obtain additional financing.  The
	Company is currently seeking collaborative arrangements with
	pharmaceutical companies for the joint development of delivery
	systems and the successful marketing of these delivery systems.  The
	Company is exploring merger opportunities or other strategic
	alternatives to fund future operations.

	In view of the Company's very limited resources, its anticipated
	expenses and the competitive environment in which the Company operates,
	there can be no assurance that its operations will be sustained for
	the duration of its next fiscal year.

Note 3 - Prepaid and Accrued expenses:

	Accrued expenses and other current liabilities - Approximately $77,000
	of accrued vacation salary and related payroll taxes due to the
	Company's employees, approximately $27,000 of study costs,
	approximately $48,000 of legal fees and approximately $20,000 of accrued
	salary and related payroll taxes due to the Company's employees are
	included in the $191,000 total. The remainder is accrued expenses and
	other current liabilities.


				 F-7

<PAGE>


Note 4 - Furniture, Fixtures and Equipment


	Furniture, fixtures and equipment is summarized as follows:


					     July 31, 2002
					     -------------
		 Equipment                     $ 510,000
		 Furniture and fixtures           40,000
		 Leasehold improvements           28,000
						 -------
						 578,000
		 Less:Accumulated depreciation   172,000
						 -------
					       $ 406,000
						 =======
Note 5 - Stockholders' equity:

	Preferred Stock -  The Company's Certificate of Incorporation
	authorizes the issuance of up to 1,000,000 shares of Preferred Stock.
	None of such Preferred Stock has been designated or issued to date.
	The Board is authorized to issue shares of Preferred Stock from time
	to time in one or more series and to establish and designate any such
	series and to fix the number of shares and the relative conversion
	rights, voting, terms of redemption and liquidation.

Note 6 - Related Party Transactions:

	Legal Fees - The Company has incurred legal fees with an officer and
	director of the Company.  These fees approximated $125,000 and $85,000
	for the years ended July 31, 2002 and 2001, respectively.

	Stockholder's Note Receivable - In April 1998, the Company lent
	$60,000 to its President.  The note was paid in full, together with all
	accrued interest, in January 2002.

	Consulting Agreement - In February 2002 the Company entered into a
	consulting agreement with John H. Klein, effective February 1, 2002
	(see Note 7 (d) ). In addition, in February 2002, Mr. Klein was elected
	as a member and Chairman of the Company's Board of Directors.

Note 7 - Commitments and Contingencies:

	(a) During January 2002, the Company entered into a consulting
	agreement, and will pay $25,000 per quarter through December 31, 2002
	for investor relations with the Trout Group, LLC.

	(b) The Company entered into an employment agreement with its
	President for a base salary of   $248,500.   The agreement provides
	for annual cost of living adjustments equal to the greater of
	the increase in the Consumer Price Index or 5% with additional
	increases and bonuses as shall be approved by the Board.  The
	agreement has a base term of three years, which became effective in
	January 2002. The agreement is thereafter renewable for additional
	one-year periods, unless the Company gives notice to the contrary.

	(c) The Company entered into an employment agreement with its Chief
	Financial Officer for a base annual salary of $125,000.  The agreement
	provides for annual cost of living adjustments equal to the greater of
	the increase in the Consumer Price Index or 5% with additional
	increases and bonuses as shall be approved by the Board.  The agreement
	has a base term of three years, which became effective in January 2002.
	The agreement is thereafter renewable for additional one-year periods,
	unless the Company gives notice to the contrary.



				      F-8


<PAGE>

	(d) The Company entered into an employment agreement with its Vice
	President Corporate Development for a base annual salary of $120,00,
	later increased by an amendment to $180,000.  The agreement as amended
	has a base term of three years, which became effective in December
	2001.  The agreement is thereafter renewable for additional one-year
	periods, unless the Company gives notice to the contrary. In addition,
	the agreement granted the employee 1,050,000 non plan options to
	purchase shares of the Company's common stock at an exercise price of
	$0.75 per share; as of the date of this report 700,000 of such options
	had vested.


	(e) The Company entered into a consulting agreement with its Chairman
	for a base annual retainer of $300,000, plus reimbursement of various
	expenses and certain success fees.  The agreement has a base term of
	one year, which became effective in February 2002.  The agreement is
	thereafter renewable for additional one-year periods, unless the
	Company gives notice to the contrary. In addition, the agreement
	granted the Chairman 1,000,000 non plan options to purchase shares of
	the Company's common stock at an exercise price of $2.40 per share; as
	of the date of this report none of such options had vested.

	(f) The Company entered into an employment agreement with its Vice
	President Formulation Development for a base annual salary of $110,000.
	The agreement provides for annual cost of living adjustments equal to
	the greater of the increase in the Consumer Price Index or 5% with
	additional increases and bonuses as shall be approved by the Board.
	The agreement has a base term of three years, which became effective in
	May 2002.  The agreement is thereafter renewable for additional one-
	year periods, unless the Company gives notice to the contrary. In
	addition, the agreement granted the employee 150,000 non plan options
	to purchase shares of the Company's common stock at an exercise price
	of $3.02 per share; as of the date of this report none of such options
	had vested.

	Leases -  In August 2000, the Company entered into a 5-year lease
	agreement, effective October 2000, for approximately 4,500 square feet
	of office, laboratory and manufacturing space.  Annual rent is
	approximately $63,000 plus real estate taxes, currently estimated to be
	approximately $11,000 annually.  Previously, the Company rented office
	space on a month to month basis.  Rent expense for the Company totaled
	approximately $75,000 and $69,000 for the years ended July 31, 2002,
	and 2001 respectively.

	Government Regulation - The development, manufacture and
	commercialization of pharmaceuticals are subject to extensive regulation
	by various federal and state government entities.  The Company cannot
	determine the impact of government regulations on the development of
	its delivery systems.

Note 8 - Income Taxes:

	No provision for current and deferred income taxes is required for
the years ended July 31, 2002 and 2001.

	The significant components of the Company's net deferred tax asset
are summarized as follows:

						     July 31
					      ----------------------
						 2002          2001
					      ----------    --------
Differences between the cash basis of
 accounting for income tax reporting
 and the accrual basis for financial
 reporting purposes                           $        -   $  (27,000)
 Net operating loss carryforwards........      2,890,000    2,003,000
					       ---------    ---------
					       2,890,000    1,976,000

 Valuation allowance                           2,890,000    1,976,000
					       ---------    ---------
Net deferred tax asset....................    $        -   $        -
					       =========    =========



				     F-9

<PAGE>


The following is a reconciliation of income tax benefit computed at the 34%
statutory rate to the provision for income taxes:


						 2002           2001
					      ----------    -----------
Federal Tax at statutory rate............     $1,459,000    $  377,000
State Income Tax.........................        257,000        48,000
Non deductible; options issued for
  services...............................       (802,000)            -
Valuation allowance......................       (914,000)     (425,000)
					       ---------     ---------
					      $        -    $        -
					       =========     =========


	A valuation allowance is provided when it is more likely than not that
some portion of the deferred tax asset will not be realized.  The Company has
determined, based on the Company's prior history of recurring losses, that a
full valuation allowance is appropriate at July 31, 2002 and 2001.

	At July 31, 2002, the Company has federal and state net operating loss
carryforwards for financial reporting and income tax purposes of approximately
$7,900,000 and $5,5000,000, respectively, which can be used to offset current
and future taxable income through the year 2023.

Note 9 - Stock Options:

	At July 31, 2002,  the Company had three plans to allow for the
issuance of stock options and other awards, the 1992 Stock Option Plan, the
1997 Stock Option Plan and the 1998 Stock Option Plan (the "Plans").  The
total number of shares of common stock reserved for issuance, either as
incentive stock options ("ISO's") under the Internal Revenue Code or as non-
qualified options,  under the 1992 and 1997 Plans is 500,000 shares each and
1,075,000 under the 1998 Plan.  ISOs may be granted to employees and officers
of the Company and non-qualified may be granted to consultants, directors,
employees and officers of the Company.  Options to purchase Company's common
stock could not be granted at a price less than the fair market value of the
common stock at the date of grant and will expire not more than ten years
from the date of grant.  ISOs granted to a 10% or more stockholder could not
be for less than 110% of fair market value or for a term of more than 5 years.

	The Company uses the intrinsic value method prescribed by APB Opinion
No. 25 to measure compensation expense.  If the fair value method had been
used to measure compensation expense as prescribed by SFAS No. 123,  net loss
would have increased by $1,440,000 or $.13 per share to $5,730,000 or $.51
per share for fiscal 2002.  There were no options granted in fiscal 2001.

	The fair value of options granted in fiscal 2002 were estimated at
the date of grant using a Black-Sholes option model with the following
weighted-average assumptions, respectively: risk-free interest rates of 5.7%
yield of 0.0% volatility factors of the expected market price of the Company's
Common Stock of 99% and a weighted-average expected life of the options of
five (5) to ten (10) years.

	The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options, which have no vesting restrictions
and are fully transferable.  In addition, option valuation models require
input of highly subjective assumptions including the expected stock price
volatility.  When the Company shares were not traded publicly, the employee
stock options had characteristics significantly different from those of
publicly traded options.  Because changes in the subjective input assumptions
can materially affect fair value estimate, in management's opinion, the
existing models do not necessarily provide a reliable single estimate of the
fair value of its employee stock options.



				    F-10

<PAGE>

	Information with respect to stock option activity is as follows (in
thousands, except exercise price amounts):



						     Outstanding Options
				Options       --------------------------------
				Available     Number of Options    Exercise
				for Grant        Options             Price
------------------------------------------------------------------------------
Balance at August 1, 2000....         -           2,300             $1.53

Grants.......................         -               -                 -

Exercises....................         -               -                 -

Cancellations................         -               -                 -
				-------          ------              ----
Balance at July 31, 2001.....         -           2,300             $1.53

Additional Shares reserved....    2,475               -                 -

Grants........................    3,378           3,378              1.60

Exercises.....................       10              10               .63

Cancellations.................    1,190           1,190              1.42
				-------          ------              ----
Balance at July 31, 2002......      277           4,478             $1.61
				=======          ======              ====

Option price per share:  $.63 - $3.18
Options exercisable:  3,328,000


	The following table summarizes significant ranges of outstanding and
exercisable options at July 31, 2002 (in thousands, except exercise price
amounts):

			  Outstanding Options           Options Exercisable
		       ---------------------------   ----------------------
			       Weighted
				Average   Weighted                Weighted
			       Remaining  Average                 Average
Range of                        Life in   Exercise                Exercise
Exercise Prices        Options   Years    Price        Options    Price
---------------------------------------------------------------------------
$0.01 - $1.00.......... 2,030    6.7      $  .74        2,030     $   .74
$1.01 - $2.00..........   860    4.1        1.84          860        1.84
$2.01 - $3.00.......... 1,188    9.5        2.44          188        2.63
$3.01 - $4.00..........   400    9.7        3.12          250        3.18
			-------------------------------------------------
			4,478    7.2      $ 1.61        3,328     $  1.38
			=================================================

	In addition to stock options issued by the Company under the Plans,
the Company has reserved 11,364,781 shares of common stock for non-plan
options and warrants as detailed below.

	Non-plan Options and Warrants - At July 31, 2002 there were
	outstanding the following classes and numbers of instruments
	exercisable for Common Stock:

	A.   680,000 Class A Warrants, issued in connection with the Public
	Offering, exercisable until November 2002, to purchase a like number
	of shares of Common Stock at an exercise price of $5.80 per share.

	B.   68,000 warrants, issued to the Underwriter in connection with
	the Public Offering, exercisable until November 2002, to purchase
	68,000 units, each consisting of one share of Common Stock and one
	Class A Warrant at an exercise price of $9.74 per unit.  Each Class
	A Warrant included in the units is exercisable on the same terms as
	is described above in paragraph A.

	C.   2,700,000 stock options, not issued under any of the plans, as
	follows:

	     * 300,000 options each issued on November 19, 1997, vesting
	       immediately, to the Company's President and former Chairman
	       of the Board of Directors, for a total of 600,000, having an
	       exercise price of $1.84 per share, issued in connection with
	       their respective employment agreements in June 1997,
	       exercisable until November 2007.



				   F-11


<PAGE>


	     * 700,000 options issued in December 2001, vesting immediately,
	       to the Company's Vice President for Corporate Development, in
	       connection with his employment agreement,  exercisable until
	       December 2011. There is a contingency in that employment
	       agreement which, if satisfied, would result in the issuance
	       of an additional 350,000 options; the Company has reserved
	       shares to meet that contingency.

	     * 1,000,000 options issued in February 2002, vesting in three
	       equal installments beginning in February 2003, to the Company's
	       present Chairman in connection with his consulting agreement,
	       having an exercise price of $2.40 per share, exercisable until
	       January 2012.

	     * 250,000 options issued in April 2002, vesting immediately, to
	       a consultant to provide investment banking assistance to the
	       Company.  These options have an exercise price of $3.18 per
	       share, exercisable until April 2012.

	     * 150,000 options issued in May 2002, vesting in three equal
	       installments beginning November 15, 2002, to the Company's
	       Vice President Formulation Development, in connection with
	       his employment agreement, having an exercise price of $3.02
	       per share, exercisable until May 2012.

	D. 60,000 warrants issued to a public relations company, exercisable
	until January 2007 at a price of $2.00.

	E. 4,000,000 warrants issued to an investor, in connection with the
	fiscal year 2002 private placement, exercisable until December 2008
	at a price of $.75.

	F. 2,666,667 warrants issued to an investor, in connection with the
	fiscal year 2002 private placement, exercisable until December 2009
	at a price of $.75.

	G. 200,000 warrants issued to a consulting company, exercisable until
	January 2010 at a price of $1.00.

	H. 200,000 warrants issued to each of two consulting companies, for
	a total of 400,000, exercisable until November 2010 at a price of
	$.75.

	I. 240,114 warrants at $.75 per share issued to broker/dealers in
	connection with the fiscal year 2001 private placement.  50,000 of
	such warrants expire in October 2010, and remaining warrants (190,114
	shares) expire in May 2011.

Note 10 - Subsequent Events:

	In October 2002 the Company 75,000 options under the 1998 option plan
	and 200,000 Non-Options Plan to its President.  These options vest
	immediately, have an exercise price of $1.30 and expire during October
	2007.

	In November, 2002, the Company decided to extend for one year the
	expiration date of its  publicly traded warrants (i.e. to November
	18, 2003). All other provisions of the warrants remain unchanged.


				   F-12

<PAGE>


				SIGNATURES

	Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Company has duly caused this Report to be signed
on its behalf by the undersigned, thereunto duly authorized.

				   NovaDel Pharma Inc.


				   By:/s/ Harry A. Dugger III
				   -------------------------------
Date: October                      Harry A. Dugger, III, President


	Pursuant to the requirements of the Securities Exchange Act of 1934,
this Report is signed below by the following persons on behalf of the Company
and in the capacities and on the dates indicated.

Signatures                      Title                         Date
-----------------------------------------------------------------------------
/s/ Harry A. Dugger, III        President and Chief Executive  Nov. 12, 2002
-------------------------        Officer (Principal and
Harry A. Dugger, III             Executive Officer) and
				 Director

/s/ Donald J. Deitman           Chief Financial Officer        Nov. 12, 2002
----------------------          (Principal Financial
Donald J. Deitman                 Officer)
(Principal Financial Officer)

/s/ John H. Klein
----------------------          Chairman of the Board and      Nov. 12, 2002
John H. Klein                    Director

/s/ Robert F. Schaul            Secretary and Director         Nov. 12, 2002
----------------------
Robert F. Schaul

/s/ Jack J. Kornreich           Director                       Nov. 12, 2002
---------------------
Jack J. Kornreich
October

/s/ Robert C, Galler            Director                       Nov. 12, 2002
---------------------
Robert C. Galler


				   F-13


<PAGE>



			       CERTIFICATION


I, Harry A. Dugger III, Ph.D., certify that:

1.  I have reviewed this annual report on Form 10-KSB of NovaDel Pharma Inc.;

2.  Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by
this annual report;

3.  Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4.  The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

    a)  Designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this annual report is being prepared;

    b)  Evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date of this
annual report (the "Evaluation Date"); and

    c) Presented in this annual report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date.

5. The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

    a)  All significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors and material weaknesses in internal controls; and

    b)  Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.  The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date:  November 12, 2002

Harry A. Dugger III, Ph.D
President & CEO

/s/ Harry A. Dugger III
-----------------------
     (Signature)



<PAGE>


			       CERTIFICATION

I, Donald J. Deitman, certify that:

1.  I have reviewed this annual report on Form 10-KSB of NovaDel Pharma Inc.;

2.  Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by
this annual report;

3.  Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4.  The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

    a)  Designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this annual report is being prepared;

    b)  Evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date of this
annual report (the "Evaluation Date"); and

    c) Presented in this annual report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date.

5. The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

    a)  All significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors and material weaknesses in internal controls; and

    b)  Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.  The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.



Date: November 12, 2002

Donald J. Deitman
Chief Financial Officer

/s/ Donald J. Deitman
-----------------------
      (Signature)




<PAGE>
	    *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *

							EXHIBIT 11


			      NOVADEL PHARMA INC.
	       (Formerly Flemington Pharmaceutical Corporation)

			EARNINGS PER SHARE COMPUTATION


						      YEAR ENDED
						    JULY 31, 2002
						   ----------------

							  BASIC
						   ----------------

Weighted average shares outstanding                      11,361,000
Dilutive effect of stock performance plans (1)                   --
						   ----------------
     Total                                               11,361,000

Net Income (loss)                                        (4,290,000)
						   ----------------

Earnings per share                                             (.38)
						   ----------------



						      YEAR ENDED
						    JULY 31, 2001
						   ----------------

							  BASIC
						   ----------------

Weighted average shares outstanding                       6,326,000
Dilutive effect of stock performance plans (1)                   --
						   ----------------
     Total                                                6,326,000

Net Income (loss)                                        (1,109,000)
						   ----------------

Earnings per share                                             (.18)
						   ----------------



	 (1) Since the company has reported a loss for each period, no
	     potential shares from stock performance plans have been
	     presented, as their effect would be anti-dilutive.













<PAGE>


	       *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *


							Exhibit 23

		       CONSENT OF INDEPENDENT ACCOUNTANTS


We hereby consent to the incorporation by reference in the Registration
Statement on Form S-8 (Registration Number 333-42103) of our report
dated October 17, 2002, on the financial statements for the two years in the
period ended July 31, 2002, which appear in the Form 10-KSB.


					      Wiss & Company, LLP

Livingston, New Jersey
October 17, 2002

















<PAGE>


	      *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *


							Exhibit 99.1

			       CERTIFICATION


	Pursuant to section 906 of the Sarbanes-Oxley Act of 2002
(subsections (a) and (b) of section 1350, chapter 63 of title 18, United
States Code), each of the undersigned officers of NovaDel Pharma Inc., a
Delaware corporation (the "Company"), does hereby certify, to the best of
such officer's knowledge and belief, that:


	(1) The Annual Report on Form 10-KSB for the year 2002 ended July 31,
2002 of the Company fully complies with the requirements of section 13 (a) or
15 (d) of the Securities Exchange Act of 1934; and


	(2)  The information contained in the Form 10-KSB fairly presents,
in all material respects, the financial condition and results of operations
of the Company.



Dated: November 12, 2002                     /s/ Harry A. Dugger III
					     -------------------------
					     Harry A. Dugger III, Ph.D
					     President & Chief Executive
					     Officer


Dated: November 12, 2002                     /s/ Donald J. Deitman
					     --------------------------
					     Donald J. Deitman
					     Chief Financial Officer